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Chapter 1 
INTRODUCTION 
1.1 Prodrug approach 
Advances in modern genomics and proteomics technologies make drug discovery much more 
complex than decades ago. Although the identification of new drug substances by high-
throughput screening has provided medicinal chemists a powerful tool of exploring more 
chemical scaffolds for better efficacy, the pharmaceutical parameters of a new molecule with 
satisfying physicochemical properties make small-molecule drug design more and more 
challenging. Compounds are generally built with proper structural features that will meet 
pharmacokinetic (PK) and pharmacodynamic (PD) criteria, as well as maintain efficacy and 
safety. However, when good biological activity unavoidably leads to problematic pharmaceutical 
or pharmacokinetic properties, resulting in a situation that is unsolvable by structural 
modification of a targeted scaffold, a prodrug approach is often considered.
1
The prodrug concept was introduced in 1958 by Adrien Albert
2
 to describe pharmacologically 
inactive therapeutics which then can be transformed in vivo to active metabolites after being 
absorbed. Prodrugs are designed to improve undesirable properties, such as poor ADMET 
(absorption, distribution, metabolism, elimination, toxicity) of pharmacologically active 
compounds. Historically, the design of a prodrug strategy was “an act of desperation”; it was 
considered only when structure-activity relationship studies could not bridge the incompatibility 
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between pharmacological activity and non-optimal pharmaceutical parameters.
3
  Many prodrug 
examples have been found to improve the drugs aqueous solubility, enhance passive intestinal 
absorption, and protect again fast metabolism, etc.
4
  Other prodrugs with efforts beyond the 
modification of physicochemical properties have also been reported targeting an intestinal 
transporter, such as valacyclovir.
5, 6
  Nevertheless, with the exploration of pharmaceutical 
sciences at the molecular level, drug delivery technologies facilitated by prodrug approaches can 
be extended to many other aspects. In recent years prodrugs designed for tissue-selective 
delivery have become an interesting area of study in addition to increasing the overall 
bioavailability.
7
  By attaching specific pro-moieties, drugs could be locally concentrated by the 
corresponding transporter (Levodopa
8
 ) /surface antigens (Gemtuzunab ozogamicin
9
 ) or special 
pro-moieties could be hydrolyzed by unique enzymes in targeted areas by selective activation.
7
  
These approaches are able to significantly reduce the concentration of parent drugs in the whole 
body circulation, thus reduce their toxicity.  
1.2 Activating Enzymes 
The prodrug approach has been successful in many therapeutic areas such as marketed anticancer, 
antiviral, anti-inflammatory agents and angiotensin-converting-enzyme inhibitors.
4, 10
  However, 
various challenges still exist and work is needed in preclinical and clinical studies to understand 
the mechanisms of enzymatic activation of prodrugs. After achieving the desire site of delivery, 
prodrugs must be converted to the active form either enzymatically or chemically prior to 
eliciting their pharmacological effect. When prodrugs are chemically activated, the effects from 
enzymatic variations are negligible. But there are only very few reported prodrugs relying purely 
on chemical activation
11, 12
 likely due to stability issues and the uncertainty of activation sites. 
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Most marketed prodrugs are activated enzymatically. There are many advantages of enzymatic 
prodrug activation although disadvantages such as interspecies differences, drug-drug 
interactions, and enzymatic polymorphisms have posed great challenges for prodrug design.  
The most common prodrugs utilize ester bonds to link the drugs to alkyls, amino acids, and 
phosphates as the pro-moieties, which are then hydrolyzed by esterases, peptidases, phosphatases, 
and other similar metabolizing enzymes after the prodrugs have been absorbed. Even though 
prodrugs contribute a clear benefit to drug development, the application of the strategy is still 
being debated as it introduces extra complexity due to the requirement of enzymatic activation.  
This activation is greatly challenged by interspecies (differences of activating ability between 
mice, dog, human)
13
 and intraspecies (genetic polymorphism of activating enzymes) 
variabilities.
14
  Thus these activating enzymes and associated mechanisms present pivotal 
obstacles toward a broader application of prodrugs. Unfortunately, the activation mechanisms 
have been lagging compared to the commercialization of many prodrugs. For example, the 
activating enzyme valacyclovirase (BPHL) for valacyclovir, which was approved by FDA in 
1995, was not identified until 2003.
15
  Dabigatran etexilate was approved in 2010 and its PK and 
pharmacodynamic parameters have been characterized in detail,
16, 17
  but its activating enzymes 
were not reported until recently.
18
  These examples highlight the present challenges and need in 
developing a mechanistic understanding of prodrug activation in drug delivery.  
1.3 Activity-Based Protein Profiling (ABPP) 
Activity-based protein profiling is a powerful chemical proteomic tool which is able to annotate 
the functions of different classes of enzymes.
19-21
  Specific chemical compounds as ABPP probes 
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are designed to target certain enzyme subclasses on an active-site-directed basis in proteomic 
samples from cell lines or animal tissues (Figure 1.1).
22-26
 
ABPP chemical probes essentially consist of three building blocks: a reactive group, a 
spacer/linker, and an analytical tag. The reactive groups with different chemical scaffolds 
covalently bind to certain subclasses of enzymes with similar functions.
27-30
  Reactive groups are 
designed and selected based on the aim of maintaining coverage for a manageable number of 
intra-class enzymes but minimizing cross-linkage with extra-class enzymes. Over the last two 
decades, many probes targeting different enzyme classes have been synthesized and used to 
characterize enzymatic functions. For example, there are fluorophosphonate probes for serine 
hydrolases,
31-33
  epoxide probes for the papain family of cysteine proteases,
23, 34
  and 
photoreactive probes for metalloproteases.
35
  All of these target tens to hundreds of enzymes in 
their subclasses and are differentiated by their enzymatic activity. Another element in an ABPP 
probe is the analytical tag, which can be a fluorophore for fluorescence visualization, biotin for 
streptavidin isolation in LC/MS identification approaches, and azide or alkyne handles for 
detection through click chemistry.
32, 36, 37
  Profiling results can be reported out in the form of 
images from a fluorescence scanner or peptide sequence data by LC-LC/MS identification
38
 
depending on which tags are used in the probe. Platforms for high-throughput screening of 
ABPP analysis have also been reported for the identification of enzyme inhibitors.
39, 40
  Reactive 
groups and analytical tags are linked together by a spacer, which can be alkyl chains, 
polyethylene glycols (PEG) or peptide sequences. Alkyl and PEG spacers will change the 
hydrophobicity of the probe, thus resulting in altered binding preferences and kinetics.
31, 41
  
When a specific peptide sequence is used as a spacer, it usually behaves as a substrate for the 
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corresponding protease, and is enzymatically cleaved to separate the binding group and 
analytical tag.
42
  
Amongst these probes, the fluorophosphonate (FP) is especially effective in the study of the 
active serine hydrolase (SH) class of enzymes
43
 which includes the activating enzymes of ester 
prodrugs.
44
  In our studies, we have utilized FP-PEG-rhodamine and FP-PEG-biotin probes 
(Figure 1.2) for the identification of ethyl ester prodrug activating enzymes.  
1.4 Carboxylesterases 
Human carboxylesterases belong to a well-conserved multigene family of α,β-hydrolase fold 
proteins, and they catalyze the hydrolysis of a variety of endogenous and exogenous compounds 
including toxins and drugs.
45
  There are at least five gene families among all of the identified 
carboxylesterases,
46
  the majority of which fall into carboxylesterase 1 (CES1) and 
carboxylesterase 2 (CES2). Human CES1 and CES2 are differentiated by their substrate 
specificity and tissue distribution. Both CES1 and CES2 have large catalytic binding sites that 
can accommodate various substrates. CES1 prefers to hydrolyze esters with small alcohol and 
large acyl groups
47
 while CES2 hydrolyzes esters of large alcohol and small acyl groups with 
higher efficiency.
48
  CES1 is highly expressed in liver and is also detectable in other tissues. 
CES1 has been reported as the activating enzyme of oseltamivir and many other ester prodrugs.
49, 
50
  Newly identified variants of CES1 and polymorphs have been reported recently to affect 
substrate activation.
51-54
  Thus, taking oseltamivir as a case study, we looked to develop a general 
approach to rapidly profile its activating enzymes, provide information on how CES1 activates 
oseltamivir and whether there are any other activating hydrolases in humans.  
6 
 
1.5 Objectives 
Due to its potential for pharmacokinetic and pharmacodynamic advantages, prodrug 
development has received increased attention. Many successful prodrugs are known to be 
activated via the hydrolysis of an ester bond by serine esterases. Our goal is to develop a general 
method by which to identify activating enzymes of various prodrugs and apply this method to 
profile the activating enzymes in different human cell lines. Towards this goal, we plan to utilize 
oseltamivir as an example to compete with FP probes in human cell lines and validate the 
competitive ABPP approach. We will then confirm the activities of the identified enzymes by 
comparison with their recombinantly overexpressed pure forms.  
In our first aim, a serine hydrolase labeling reagent, FP-PEG-Biotin was synthesized via a novel 
and safe route. A biotinylated fluorophosphonate (FP-PEG-biotin) was previously synthesized as 
an effective probe for activity-based protein profiling (ABPP).
31
  The reactive group, 
fluorophosphonate, specifically targets active serine hydrolases and is inactive towards denatured 
proteins. The biotin group, which is attached to FP group by a PEG linker, can pull down the 
labeled proteins by interacting with streptavidin. This probe was synthesized via a novel route 
proceeding by first building up a biotin-PEG-phosphonate linker fragment, and then completing 
it by modifying the phosphonate ester to a fluorophosphonate in the last step. This route has the 
capability to provide sufficient quantities of the FP-PEG-biotin probe, which can be utilized in 
the identification and purification of enzymes.  
The second aim is to validate competitive ABPP between prodrugs and the FP probe, visualizing 
the interactions via 1D SDS-PAGE and identifying the activating enzyme via mass spectrometry, 
as illustrated in figure 1.3. FP probes are capable of binding non-specifically to serine hydrolases 
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in a Caco-2 cell homogenate. However, if the homogenate is treated first with prodrugs, such as 
oseltamivir, the FP binding of activating enzymes will be greatly reduced due to a competition 
between the prodrug and probe. The degree of reduction as reflected in the change of band 
intensities can be visualized by fluorescence imaging. The targeted enzyme could then be 
subjected to mass spectrometry analysis for identification.  
Thirdly, we confirmed enzymatic activation with corresponding recombinantly overexpressed 
enzymes. A selective CES1 inhibitor, WWL50, was characterized by an advanced technology 
“ABPP-SILAC”. The enzymatic hydrolysis of several ethyl ester prodrugs was totally inhibited 
in human cell homogenates with WWL50 pre-treatment, confirming that CES1 is the 
predominant activating enzyme for ethyl ester prodrugs.  
The proteomic strategy outlined in this study should help us elucidate the activation process of 
ester prodrugs and in turn accelerate the development of prodrug activation mechanism studies 
that contribute to the design of effective drug delivery systems. 
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1.6 Figures 
 
Figure 1.1 Schematic diagram of the mechanism of ABPP. (a) General strategy of profiling 
enzymes by LC-LC/MS in specific subclasses with similar activity. RG, reactive group; BG, 
binding group; TAG, analytical tage, biotin or rhodamine. (b) Inhibitor discovery and selectivity 
profiling in whole proteome samples (adopted from Saghatelian and Cravatt 2005.20 ). 
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Figure 1.2. Chemical structures of serine hydrolase probes.  
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Figure 1.3 Competitive ABPP between FP probes and prodrugs. The enzymatic binding of 
FP probe is kinetically competed by the catalytic reactions of enzymatic substrate. 
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Chapter 2 
SYNTHESIS OF FLUOROPHOSPHONATE – POLYETHYLENEGLYCOL – BIOTIN  
2.1 Introduction 
One of the goals of chemical biology is to develop small molecule and biomolecule-based probes 
to interrogate biological processes. In this regard, fluorophosphonate (FP) probes have been 
extensively used in activity-based protein profiling (ABPP) in proteomic studies.
1, 2
  FP probes, 
specifically designed to target serine hydrolases, originated from diisopropyl fluorophosphonate 
(DFP).
3, 4
  DFP is a serine hydrolase covalent inhibitor and from it have evolved analytical tools 
in which “handles“, such as biotin, rhodamine, and alkyne have been appended via a variety of 
linking chains.
5-8
  These FP analogues have proven to be powerful tools in the profiling of 
complex proteome samples
9
 and in the identification of selective inhibitors.
10, 11
  However, very 
few cases have been published in which these probes have been utilized in the study of enzymes 
with reversible substrates. These substrates are usually endogenous or exogenous organic 
molecules of small molecular weight, like ethyl ester prodrugs, exhibiting enzymatic kinetic 
properties different from other inhibitors due to their high turnover rates.  Thus, competition 
assays between substrates and FP probes are more difficult to perform due to the rapid kinetics 
and covalent binding properties of the probes. 
The FP-PEG-biotin compound 1, shown in figure 2.1, was first synthesized by the Cravatt group 
and utilized for affinity isolation of enzymes by pull-down with avidin beads followed by mass 
16 
 
spectrometry analysis.
12
  Our interest in generating 1 on a larger scale to use in our research led 
us to consider an alternative and more expeditious synthetic route. This was driven by several 
concerns of the original route including (a) a poor overall yield (b) challenges in the 
chromatographic purification of some intermediates due to their hydrophilicity and lack of a UV 
chromophore, and (c) generating and then carrying the fluorophosphonate moiety through two 
steps with an attendant concern of its high reactivity and potential for toxicity to the laboratory 
chemist.
12, 13
  In our efforts to address those shortcomings, we report a novel synthetic route to 
FP-PEG-biotin 1, and in its following validation in which this probe was utilized in competitive 
ABPP experiments with ethyl ester prodrug. 
2.2 Results 
Synthesis 
The route to target probe 1 is delineated in scheme 2.1  Monobenzylation of tetraethylene glycol 
2 was carried out by the procedure of Jiang et al.
14
  to give ether 3 in 78% yield.  This was then 
subjected to a two-step procedure to provide the novel iodo-ether 4b. Thus, tosylation of 3 
utilizing a slight modification of literature conditions
15
 gave 4a, which was subjected to 
Finkelstein conditions utilizing a procedure reported for a related compound
16
 to afford 4b in a 
combined 90% yield.  The phosphonate moiety was installed under standard Arbuzov conditions 
by refluxing 4b in neat triethyl phosphite for 1 h to provide novel intermediate 5 in 92% yield 
following purification by column chromatography. Clean removal of the benzyl protecting group 
under standard conditions of catalytic hydrogenolysis provided in 96% yield the known 
phosphonate polyether alcohol 6, the synthesis of which had been accomplished earlier by a 
different route.
17
  Activation of the alcohol moiety of 6 to the succinimidyl carbonate 7 was 
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carried out under standard conditions in 87% yield following chromatographic purification.  
Coupling of 7 to the in situ generated 5-(biotinamido)pentaneamine fragment 12, made from 
Boc-protected diamine 10 in a known two-step process,
18
  was carried out under mild conditions 
to provide novel precursor 8 in 76% yield following purification. The stage was now set for a 
two-step modification of the phosphonate moiety.  Reaction of 8 with lithium azide in hot DMF, 
under conditions developed for the monodealkylation of phosphonic acid dialkyl esters of 
nucleosides,
19
  provided the novel monoethyl ester 9 in 87% yield following purification by a 
two-stage chromatographic procedure. Penultimate intermediate 9 was then cleanly converted to 
the fluorophosphonate utilizing the standard fluoridating reagent (DAST in dichloromethane) at -
42 ºC. Workup provided the FP probe 1 
20 
in 80% yield, which was pure enough to use directly 
in biological studies.  Due to the absence of a UV chromophore, the purity of FP-PEG-biotin 1 
could not be determined by HPLC. TLC analysis was also problematic due to its reactivity with 
the highly polar solvent mixture required to move it up a plate.  Nevertheless, we deem 1 to be of 
high purity due to the cleanliness of its NMR spectra (
1
H, 
13
C, 
19
F, 
31
P).  The structural 
assignments of all compounds were supported by diagnostic peaks in the 
1
H and 
13
C NMR 
spectra and by mass spectrometry.  
Kinetic study of FP probe labelling activity 
An incubation time control study is key toward successfully monitoring competition between FP-
PEG-biotin 1 and a prodrug as a reversible substrate with a high turnover rate. Hence, over a 
long incubation time, the prodrug will be competed out with the active enzyme covalently linked 
to the FP probe even though the concentration of added prodrug is high compared to the probe.  
Enzymes present different kinetic properties in the same proteome sample, and a single enzyme 
can have different preferences for FP probes with different linkers.
21
  Thus it is important to 
18 
 
perform kinetic studies on a specific tissue or cell line before the start of competition assays. 
Toward this end, Caco-2 cell homogenate samples were prepared and incubated with FP-PEG-
biotin 1 over different time courses ranging from 1- 30 minutes (Figure 2.2). The sample from 
each trial was then separated by SDS-PAGE and blotted by alkaline phosphatase conjugated 
streptavidin.  A proteome sample was also incubated with DMSO for 10 minutes as a control. As 
all competitive exchanges between the FP probe and prodrugs occur within less than a 15 minute 
window, data collection was limited to 30 minutes. 
The band intensities from endogenous streptavidin-binding proteins, indicated in the control 
lane, did not change with incubation time. Neither did the intensity of the band around 64-kD 
(thin arrow), suggesting that this protein bound to the FP probe very fast (~50% within 1 
minute). In contrast, the 49-kD enzyme band (hollow arrow) showed a clear time-dependent 
reaction. Due to their lower expression levels, reaction of 1 with other enzymes (dark arrows) 
could not be detected until 10 minutes incubation time. Therefore, depending on the type and 
expression levels of serine hydrolase being investigated, different incubation times are required 
in order to observe a clear signal. 
Competition study 
To assess the possibility and potency of utilizing FP-PEG-biotin in the identification of prodrug 
activating enzymes, oseltamivir was chosen as an example to compete with 1. Oseltamivir 
(Tamiflu
®
) is a commercially available prodrug, which is converted to oseltamivir carboxylate 
(O.C.) after being absorbed in gastrointestinal tract. Carboxylesterase 1 (CES1),
22
  a common 
esterase existing in multiple human tissues, has been shown to be active in the oseltamivir 
hydrolysis.
23
  Caco-2 cell homogenate (1 mg/mL) in Tris buffer (50 mM, pH 7.4) was treated 
with oseltamivir (10 mM final) or vehicle (as control) for 10 min at room temperature and then 
19 
 
treated with FP-PEG-biotin (concentration as noted in figure 2.3) for 1 or 5 min. Western blot 
analysis showed a clear reduction in band intensity around 60-70 kDa due to oseltamivir 
competition while signals from the rest of the protein bands remained the same. The reduced 
band intensity suggested the feasibility of applying FP-PEG-biotin 1 to the study of prodrug 
activating enzymes identification. 
 
2.3 Discussion 
Fluorophosphonate probes with different analytical handles, such as rhodamine and alkyne, are 
being used to identify and characterize the proteome samples from cell or animal tissue.
8
  Biotin-
based probes that bind to streptavidin play an essential role in isolating and analysing serine 
hydrolases. In our studies with FP-PEG-biotin probe 1, we required sufficient enough quantities 
that we decided to re-engineer the original synthesis of Kidd et al.
6
  Our major modifications 
involved (a) introduction of a benzyl protecting group (in place of the TBS of the original 
synthesis) onto the PEG moiety to facilitate the early stages of the synthesis by providing a UV 
active chromophore for easy detection; (b) introduction of a high yielding two-step iodination 
process, which avoids chromatography; (c) reversing the sequence of fluoridation and amidation 
reactions such that the reactive FP moiety can be introduced in the last step.  Overall, these 
modifications make for a more scalable, higher yielding synthetic scheme and importantly 
isolates the handling of reactive and potentially toxic FP compounds to a single step, namely the 
last one.    
FP probes have been used mostly in the enzymatic annotation and development of covalent 
inhibitors for pharmacologically interesting serine hydrolases due to their strong binding and 
rapid labelling properties. We have shown that for serine hydrolases with reversible substrates, 
20 
 
FP probes can be useful tools if their concentration and incubation times are properly controlled, 
as demonstrated in the competitive ABPP between oseltamivir (10 mM) and FP-PEG-biotin 
probe in Caco-2 cell line. 
In summary, several steps of the original synthesis of FP-PEG-biotin probe 1 have been 
modified, leading to a higher overall yield and easier manipulation.  Starting from common 
precursor 2, our synthesis requires only four chromatographic purifications over nine steps and 
provides a 28.5% overall yield of 1.  In contrast, the Cravatt sequence requires six 
chromatographic purifications over eight steps with an overall yield of 1%. The subsequent 
kinetic study and competition of probe 1 with oseltamivir have shown that FP probes can be 
utilized for investigation of prodrug activating enzymes as long as sufficient control is taken to 
kinetically tune the time and probe concentration of reaction. 
2.4 Experimental Methods 
All reagents were commercially available and used without further purification. 
1
H and 
13
C 
NMR spectra were obtained on Bruker 300 or Bruker 500 MHz spectrometers with CDCl3, d6-
DMSO, or d4-methanol as solvent, and chemical shifts are reported relative to the residual 
solvent peak in δ (ppm).  Mass spectrometry analysis was performed using a Waters LCT time-
of-flight mass spectrometry instrument. Flash column chromatography was performed with 
silica gel (220-240 mesh). Thin-layer chromatography (TLC) was performed on silica gel 
GHLF plates (250 microns) purchased from Analtech.  Developed TLC plates were visualized 
with a UV lamp at 254 nm or by iodine staining.  Extraction solutions were dried over MgSO4 
prior to concentration. 
1-Phenyl-2,5,8,11-tetraoxatridecan-13-yl 4-methylbenzenesulfonate (4a) 
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This compound was made by a slight modification of the literature procedure.
15
  An ice-cold 
solution of tetraethylene glycol monobenzyl ether (3; 13.9 g, 48.9 mmol; made by the 
procedure of Jiang et al.
14
) in 70 mL of THF was treated with KOH (9.85 g, 171.1 mmol) 
dissolved in 50 mL of water. A solution of p-toluenesulfonyl chloride (11.18 g, 58.7 mmol) in 
36 mL of THF was added dropwise to the reaction mixture, which was then gradually warmed 
to room temperature and stirred overnight. The reaction mixture was poured into sat. aq. 
ammonium chloride and extracted with dichloromethane (3x). The combined extracts were 
dried and concentrated to leave 21.11 g (98%) of 4a as a light yellow oil: Rf  0.26 (hexanes : 
ethyl acetate, 1 : 1); 
1
H NMR (CDCl3, 300 MHz)  7.77-7.80 (d, J = 8 Hz, 2H), 7.26-7.34 (m, 
7H), 4.56 (s, 2H), 4.14 (t, J = 4.5 Hz, 2H), 3.58-3.69 (m, 14 H), 2.44 (s, 3H); 
13
C NMR (CDCl3, 
75 MHz)  144.8, 138.2, 132.9, 129.8, 128.4, 128.0, 127.7, 127.6, 73.2, 70.7, 70.6, 70.5, 69.4, 
69.2, 68.6, 21.7; MS m/z 461.0 (M+Na)
+
.  
13-iodo-1-phenyl-2,5,8,11-tetraoxatridecane (4b) 
The synthesis of 4b utilized a procedure reported for a related compound.
16
  A mixture of KI 
(23.97 g, 144.4 mmol) and sulfonate ester 4a (21.11 g, 48.14 mmol) in 250 mL of acetone was 
refluxed for 18 h.  After cooling to room temperature, the reaction mixture was filtered and the 
collected salts were rinsed with acetone.  The filtrate was concentrated to an oil that was diluted 
with dichloromethane.  The solution was washed sequentially with sat. aq. Na2S2O3 and brine,  
dried, and concentrated to give 17.44 g (92%) of 4b as a clear oil: Rf  0.37 (hexanes : ethyl 
acetate, 2 : 1) ; 
1
H NMR (CDCl3, 300 MHz)  7.26-7.35 (m, 5H), 4.57 (s, 2H), 3.63-3.77 (m, 
14H), 3:.24(t, J = 6.5 Hz, 2H); 
13
C NMR (CDCl3, 75 MHz)  138.3, 128.4, 127.7, 127.6, 73.2, 
72.0, 70.7, 70.68, 70.63, 70.2, 69.4, 3.0; MS m/z 416.9 (M+Na)
+
. 
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Diethyl (1-phenyl-2,5,8,11-tetraoxatridecan-13-yl)phosphonate (5) 
Iodo benzyl polyether  4b (17.44 g, 44.23 mmol) and triethyl phosphite (32 mL, 183.9 mmol) 
were mixed in an oven-dried round-bottom flask, and refluxed for 1 h. Excess triethyl 
phosphite was removed under vacuum and the reaction mixture was directly loaded onto a 
silica gel column, which was eluted with ethyl acetate and then methanol : ethyl acetate (5 : 95). 
Product fractions were combined and concentrated to give 16.5 g (92%) of 5 as a light yellow 
oil: Rf  0.11 (ethyl acetate); 
1
H NMR (CDCl3, 500 MHz)  7.27-7.33 (m, 5H), 4.55 (s, 2H), 4.06 
(q, J = 7 Hz, 4H), 3.6 (m, 14H), 2.05-2.16 (m, 2H), 1.30 (t, J = 7 Hz, 6H); 
13
C NMR (CDCl3, 
125 MHz)  138.2, 128.4, 127.7, 127.6, 73.2, 70.66, 70.63, 70.4, 70.2, 69.4, 65.1, 61.65, 61.60, 
27.5, 26.5, 16.46, 16.42; MS m/z 405.1 (M+Na)
+
. 
Diethyl (2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl)phosphonate (6) 
A mixture of diethylphosphonate polyether 5 (3g, 7.4 mmol), 10% Pd/C (0.3 g) and 100 mL 
ethanol in a 250 mL hydrogenation vessel was hydrogenated at 40 psi H2 for ~ 20 h. The 
reaction mixture was rapidly filtered over Celite, and concentrated under reduced pressure to 
give 2.23 g (96 %) of 6 as a clear oil: The 
1
H and 
13
C NMR are the same as previously reported 
for 6 made by a different procedure;
17
  MS m/z 315.1 (M+H)
+
. 
2-(2-(2-(2-(Diethoxyphosphoryl)ethoxy)ethoxy)ethoxy)ethyl (2,5-dioxopyrrolidin-1-yl) 
carbonate (7) 
A mixture of diethylphosphonate polyether alcohol 6 (0.5 g, 1.6 mmol), N, N-disuccinimidyl 
carbonate (2.04 g, 8 mmol), triethylamine (1.1 mL, 8 mmol), and anhydrous acetonitrile (4.5 
mL) was stirred at room temperature for 12 h.  The mixture was concentrated to an oil that was 
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distributed between dichloromethane and water. The organic phase was dried and concentrated 
to a yellow oil that was then purified by silica gel chromatography. Elution with 
dichloromethane : methanol  (98 : 2 to 95 : 5) followed by pooling and concentration of product 
fractions provided 0.64 g (87%) of 7 as a light brown oil: The 
1
H and 
13
C NMR are the same as 
previously reported for 7 made by a different procedure;
17
  MS m/z 456.1 (M+H)
+
. 
2-(2-(2-(2-(Diethoxyphosphoryl)ethoxy)ethoxy)ethoxy)ethyl (5-(5-((3aS,4S,6aR)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)pentyl)carbamate (8) 
A solution of in situ synthesized 5-(biotinamido)pentaneamine, trifluoroacetic acid salt, 12 (see 
below) in 2 mL of DMF was treated with triethylamine (0.4 mL) at 0 ºC and stirred at room 
temperature for 10 min. Diethylphosphonate polyether succinimidyl carbonate 7 (145 mg, 0.31 
mmol) was then added and the solution was stirred at room temperature overnight. The reaction 
mixture was distributed between ethyl acetate and brine, and the organic phase was dried.  
Concentration left a brown oil that was purified by silica gel chromatography eluting with 
dichloromethane : methanol: NH4OH (92 : 8 : 0.5 to 90 : 10 : 1). Product fractions were pooled 
and concentrated to leave 324 mg (76%) of 8 as a pale white solid: 
1
H NMR (CDCl3, 500 MHz) 
 6.66 (br s, 1H), 6.61 (br s, 1H), 6.03 (br s, 1H), 5.42 (br s, 1H), 4.46 (t, J = 6 Hz, 1H), 4.26 (t, 
J = 6 Hz, 1H), 4.14-4.12 (m, 2H), 4.06-4.02 (m, 4H), 3.64-3.58 (m, 12H), 3.15-3.06 (m, 7H), 
2.84 (dd, J = 5 Hz, 13 Hz, 1H), 2.69 (d, J = 13 Hz, 1H), 2.13 (t, J = 7.3 Hz, 2H), 2.10-2.05 (m, 
2H), 1.63-1.59 (m, 4H), 1.45-1.37 (m, 6H), 1.29-1.25 (m, 6H); 
13
C NMR (CDCl3, 125 MHz)  
173.4, 164.2, 156.6, 70.5, 70.4, 70.1, 69.6, 65.0, 63.7, 61.8, 61.7, 61.6, 60.2, 55.7, 40.6, 40.5, 
39.2, 35.8, 29.5, 28.9, 28.2, 28.0, 27.4, 26.3, 25.7, 23.9, 16.4, 16.3; MS m/z 669.2 (M+H)
+
. 
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2-(2-(2-(2-(Ethoxy(hydroxy)phosphoryl)ethoxy)ethoxy)ethoxy)ethyl (5-(5-((3aS,4S,6aR)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)pentyl)carbamate (9) 
A mixture of lithium azide (200 mg, 4.1 mmol), diethylphosphonate polyether carbamate 8 
(150 mg, 0.22 mmol), and 2 mL of DMF was stirred at 95 ºC for 18 h. DMF was removed 
under vacuum to leave a yellow oil, which was diluted with water and loaded onto a column of 
Amberlite – IR120 (H+) resin.  The column was eluted with DI water and the collected eluate 
was evacuated at 30 mm/Hg with stirring for 30 min at rt (to draw off hydrazoic acid), and then 
lyopholized to leave a crude yellow residue that was purified by flash chromatography. 
Gradient elution with dichloromethane : methanol : NH4OH (70 : 30 : 2 and then 80:20:1) 
followed by pooling and concentration of product fractions left 0.125 g (87%) of 9 as a 
colorless solid: 
1
H NMR (CD3OD, 500 MHz)  4.50-4.53 (m, 1H), 4.31-4.34 (m, 1H), 4.18 (t, J 
= 4.6 Hz, 2H), 3.89-3.95 (m, 2H), 3.76-3.62 (m, 12H), 3.18-3.28 (m, 3H), 3.12 (t, J = 7 Hz, 2H), 
2.95 (dd, J = 4.9 Hz, 12.9 Hz, 1H), 2.73 (d, J = 12.9 Hz, 1H), 2.22 (t, J = 7.3 Hz, 2H), 1.97-
1.91 (m, 2H), 1.80-1.37 (m, 12H), 1.26 (t, J = 7 Hz, 3H); 
13
C NMR (CD3OD, 125 MHz)  
174.5, 164.7, 157.3, 69.8, 69.7, 69.5, 69.2, 66.7, 63.4, 62.0, 60.2, 59.6, 55.6, 40.3, 39.7, 38.9, 
35.5, 29.2, 28.7, 28.4, 28.1, 28.0, 25.6, 23.8, 15.9, 15.8; MS m/z 641.2 (M+H)
+
. 
2-(2-(2-(2-(Ethoxyfluorophosphoryl)ethoxy)ethoxy)ethoxy)ethyl (5-(5-((3aS,4S,6aR)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)pentyl)carbamate (FP-PEG-
biotin; 1) 
To a solution of monoethylphosphonate polyether carbamate 9 (46 mg, 0.072 mmol) in 1 mL of 
anhydrous dichloromethane at -42 ºC was added (diethylamino)sulfur trifluoride (DAST; 
26.4μL, 0.022 mmol). The mixture was stirred for 30 min and quenched with water at -42ºC. 
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After stirring at room temperature for 10 min, the mixture was extracted with dichloromethane 
(3x). The organic phase was dried and concentrated to a yellow oil that was evacuated under 
high vacuum to leave 32 mg (70%) of 1, which was used directly in biological studies: 
1
H 
NMR (CDCl3, 500 MHz)  6.38 (br s, 1H), 5.60 (br s, 1H), 5.36 (br s, 1H), 5.29 (bs, 1H), 4.51 
(m, 1H), 4.40-4.21 (m, 5H), 3.90-3.55 (m,12H), 3.30-3.11 (m, 5H), 2.92 (dd, J = 4.9, 12.9 Hz, 
1H), 2.74 (d, J = 12.9 Hz, 1H), 2.35-2.18 (m, 4H), 1.85-1.40(m, 12H); 1.31 (t, J = 6.0 Hz, 3H); 
13
C NMR (CDCl3, 125 MHz)  173.3, 163.9, 156.6, 70.5, 70.4, 69.6, 64.2, 63.7, 63.6, 63.5, 
61.8, 60.2 55.7, 40.6, 39.2, 35.8, 29.5, 28.9, 28.1, 28.0, 26.8, 25.7, 24.9, 23.8, 16.4, 16.3; 
19
F 
NMR (CDCl3, 282 MHz)  -59.4, -63.2; 
31
P NMR (CDCl3, 121 MHz)  32.8, 24.0; MS m/z 
643.2 (M+H)
+
. 
tert-Butyl (5-(5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanamido)pentyl) carbamate (11) 
This compound was made by the procedure of Konoki et al.
18
 from tert-butyl (5-aminopentyl) 
carbamate (10; made by the procedure of Kaur et al
24
) and D-biotin.  The 
1
H NMR spectrum is 
the same as previously reported;
18
  
13
C NMR (CDCl3, 125 MHz)  173.3, 164.2, 156.2, 79.1, 
61.8, 60.2, 55.8, 40.5, 40.3, 39.2, 36.0, 29.7, 29.1, 28.4, 28.2, 28.0, 25.8, 23.9; MS m/z 451.1 
(M+Na)
+
. 
N-(5-Aminopentyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanamide (12) 
This compound was made similar to the procedure of Konoki et al.
18
  To an ice-cold solution of 
t-butyl 5-(biotinamidopentyl)carbamate (11; 136 mg, 0.32 mmol) in dichloromethane (2.0 mL) 
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was added dropwise trifluoroacetic acid (1.0 mL).  The cooling bath was removed and the 
mixture was stirred for 2 h. The solution was concentrated in vacuo to a yellow oil, which was 
used in the next step without further purification: 
1
H NMR (CD3OD, 300 MHz)  4.45 (dd, J = 
8.0, 5.5 Hz, 1H), 4.26 (dd, J = 7.5, 4.5 Hz, 1H), 3.15-3.11 (m, 3H), 2.90-2.85 (m, 1H), 2.67-
2.61 (m, 3H), 2.16 (t, J = 7.5 Hz, 2H), 1.71-1.48 (m, 4H), 1.42-1.33 (m, 8H); MS m/z 329.1 
(M+H)
+
. 
Material for Biological Experiments 
Oseltamivir was purchased from Allichem LLC. Cell culture reagents were obtained from 
Invitrogen (Rockville, MD), and the cell culture supplies were obtained from Corning (Corning, 
NY) and Falcon (Lincoln Park, NJ). 
Preparation of cell proteome samples 
The human colon carcinoma cell line, Caco-2 (from ATCC, HTB-37), was grown in complete 
medium (DMEM with 1% nonessential amino acid and 10% FBS) in 100 mm tissue culture 
dishes in an atmosphere of 5% CO2 at 37 °C. The cells were grown until 13-14 days post-
confluence before harvest. Caco-2 cells were collected in ice-cold 50 mM Tris buffer (pH 7.4), 
and immediately Dounce homogenized and sonicated at 0 °C. The resulting sample was 
centrifuged for 45 min at high speed (100,000 x g at 4 °C). The supernatant was removed and 
kept at 0 °C, and then the pellet was sonicated in a small amount of Tris buffer at 0 °C and 
centrifuged again (100,000 x g at 4 °C for 45 min). The washing step was repeated twice and all 
the supernatants were combined and saved as a cytosolic proteome fraction. The final pellet was 
resuspended by sonication in 50 mM Tris buffer containing 0.25 M sucrose and saved as 
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membrane proteome fraction. Protein concentration was determined by the BCA assay and 
aliquots of the proteome were stored at -80 °C. 
Competitive ABPP Between FP-PEG-biotin and Oseltamivir 
Caco-2 cytosol fraction (1 mg/mL) in 50 mM Tris buffer (pH 7.4) was incubated with 
oseltamivir (10 mM) for 10 min at room temperature. FP-peg-biotin (0.1, 0.5, 2 μM) or vehicle 
was then added to the sample and incubated for 1 or 5 min before being quenched with 5 x 
sample loading buffer, followed by subsequent heating at 85 °C for 5 min. The treated samples 
were subjected to 4-20% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE; Invitrogen Corporation) at 125 v for 90 min. The gel was then electrophoretically 
transferred onto a Hybond PVDF membrane (Amersham, UK). The membrane was blocked in 
Tris buffer saline with 0.1% tween-20 (TBS-T) containing 1% casein for 1 h at room temperature, 
followed by incubation with streptavidin alkaline phosphatase (1:2500 dilution) (R & D, 
Minneapolis, MN) in TBS-T at room temperature for 1 h. The membrane was washed with TBS-
T three times, 10 min for each washing. The blot was subsequently visualized with ECF 
substrate (GE Healthcare, NJ) on a Typhoon 9200 Variable Mode Imager (GE Healthcare, NJ). 
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2.5 Figures 
 
 
Figure 2.1. Structure of FP-PEG-biotin 1. 
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Figure 2.2. Kinetic study on FP labelling reactions. Caco-2 cell homogenates (1 mg/mL) were 
treated at room temperature with FP-PEG-biotin 1 (4 μM) for the indicated times, followed by 
the termination of reaction with 5x SDS-PAGE loading buffer. The results were analysed by 4-
20% SDS-PAGE gel and streptavidin blotting. Serine hydrolases which reacted with the FP 
probe in a time-dependent manner are highlighted (thin, hollow and dark arrows, respectively). 
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Figure 2.3. Western blot of oseltamivir competition assay with FP-PEG-biotin. Caco-2 cell 
homogenate was treated with tris buffer or oseltamivir solution (10 mM in tris buffer) for 10 min 
at room temperature, following the addition of FP-PEG-biotin (0.1, 0.5 or 2 μM) and was 
incubated for another 1 or 5 min. The sample was separated by SDS-PAGE, transferred to PVDF 
membrane, blocked by alkaline phosphotase-strepavidin. The competition was visualized by 
monitoring the fluorescent signal after treated with ECF. 
 
 
 
 
MW
(kDa)
115
64
37
26
182
     FP (μM): 0.1        0.1       0.5       0.5          2          2         0.1        0.1      0.5       0.5          2         2    
Osel. (mM):   0         10         0          10          0         10          0         10         0         10          0        10  
1 min 5 min
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Scheme 2.1. Synthetic route of FP-PEG-biotin probe 1 
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CHAPTER 3 
VALIDATION OF ABPP APPROACH IN THE IDENTIDICATION OF OSELTAMIVIR 
ACTIVATING ENZYMES  
3.1 Introduction 
Activity-based protein profiling (ABPP) is able to identify various classes of enzymes through 
the use of chemical probes.
1-3
  Chemical probes have been designed for different enzyme classes 
and have been used for the characterization of selective inhibitors
4-7
 and enzyme annotation.
8-11
  
Among these, the fluorophosphonate (FP) probes are especially effective in the study of the 
active serine hydrolases (SHs).
12
  Competition experiments between FPs and inhibitors have 
been extensively reported, however only a few have dealt with competitive ABPP between FPs 
and substrates with high turnover rates.
13
  In this chapter we performed competitive assays 
between FP-PEG-rhodamine (FP-PEG-rh) and oseltamivir, an ethyl ester prodrug. The 
competitive ABPP approach for the identification of ethyl ester prodrug activating enzymes was 
validated using oseltamivir as a case study. 
The prodrug activation step, typically hydrolysis, is achieved enzymatically by hydrolases. There 
are ~240 serine hydrolases (SHs) in the human genome;
14
  even for the carboxylesterases (CESs), 
there are several different families.
15
  With such an enormous number of enzymes, the prodrug 
activation pathways have been investigated in case by case studies.  Prodrug development would 
best be done with early knowledge of the specific activation pathways, i.e. specific enzymes 
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involved with the prodrug activation. The development of the ABPP approach to rapidly and 
extensively identify prodrug activating enzymes would aid prodrug optimization and 
development. 
Oseltamivir was selected as a representative classical ethyl ester prodrug (Figure 1) for our 
studies. Transforming the parent molecule, oseltamivir carboxylate (O.C.), to the ethyl ester 
significantly increases the oral bioavailability from < 5% to 80%.
16
  Human liver 
Carboxylesterase 1 (CES1) has been reported as the activating enzyme of oseltamivir.
17
  Here we 
assayed the concentration and incubation time of FP-PEG-rh with oseltamivir in on-gel 
competitive ABPP experiments and from these derived a kinetic mechanism. After a broad 
survey of Caco-2 cell homogenates, CES1 was identified as one of the binding enzymes of 
oseltamivir by LC-LC/MS.  
3.2 Results 
FP-PEG-rh Inhibits Oseltamivir Hydrolysis to Buffer Hydrolysis Level 
To successfully identify hydrolases utilizing the competitive ABPP approach, it is necessary to 
choose the right molecular probes. Although many hydrolases are recognized as SHs, it is 
essential to verify that the FP-PEG-rh probe can target all of the hydrolases capable of activating 
oseltamivir in whole cell homogenates. The human intestine is considered as the first site where 
prodrug hydrolysis occurs; we therefore chose the human colorectal adenocarcinoma (Caco-2) 
cell line to start our studies. Following pre-incubation with or without FP-PEG-rh for 30 min, we 
monitored the hydrolysis of oseltamivir in cytosolic and membrane fractions of Caco-2 lysate (2 
mg/mL). As illustrated in figure 3.1, oseltamivir hydrolysis in Caco-2 cytosolic and membrane 
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fractions was reduced to buffer level by pre-treatment with FP-PEG-rh. The results indicated that 
all of the oseltamivir hydrolases can be bound by FP-PEG-rh. 
Identification of CES1 as One Binding Enzyme by Competitive ABPP 
Oseltamivir, a good enzyme substrate with rapid on/off kinetics, was used to compete with an FP 
probe which covalently links to enzymes. A longer incubation time or higher concentration of 
the probe will readily lead to the disappearance of the substrate competition signal. Thus a time 
and concentration dependent kinetic study is necessary to observe the most significant 
competition between prodrug and probe. In addition, different probes may exhibit different 
binding kinetics toward different enzymes. Therefore, a competition study at different time and 
concentration conditions between probes and substrates is critical for this approach to be 
successful. 
We initially evaluated the competition in Caco-2 cytosolic and membrane fractions (Figure 3.2A 
and 3.2B). The best conditions showing a clear competition was with the FP probe (0.25 μM) 
incubating for 1 min, which would minimize the appearance of other low expressing enzymes. 
Longer FP incubation times showed more protein bands on the gel, and eventually abolished the 
competition signal. Thus, there is always a balance between the observance of all the protein 
bands and the most significant competition signal. Three protein bands (A, B and C), showing 
the most pronounced signal differences, are labeled by red arrows in figure 3. Protein bands A 
and C were competed for by oseltamivir in the Caco-2 cytosolic fraction. Band A was rapidly 
labeled by the FP probe upon increasing the probe incubation time or concentration; however 
band C was still observable even with a 5 min FP incubation time. This suggests that band A 
exhibits a higher turnover rate against oseltamivir than band C. The fluorescence signal of band 
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B binding to the FP probe was surprisingly enhanced by the binding of oseltamivir. This 
“reversed competition” or enhancement of signal was more prominent in the membrane fraction 
(Figure 3.2B). 
The oseltamivir concentration-dependence study was then performed under the optimized 
conditions using the FP (0.25 μM) for 1 min (Figure 3.2C). Oseltamivir at 20 mM readily 
abolished the signals of bands A and C, while enhancing that of band B. The competition was 
observable even at 5 mM oseltamivir. 
 In order to identify bands A, B and C, we treated the proteome sample with FP-PEG-biotin, 
pulled down the proteins with streptavidin agarose beads (Thermo Scientific), separated the 
accumulated serine hydrolases (SHs) by SDS-PAGE (Figure 3.3), excised the bands, and 
analyzed each by LC-MS/MS. Band A was identified as a mixture of human liver 
carboxylesterase 1 (CES1) and carboxylesterase 2 (CES2) (Table 3.1). Based on a previous 
report
17
 and our experiments (data not shown), CES2 is not the activating enzyme of oseltamivir. 
Thus CES1 was identified as one of the potential activating enzymes of oseltamivir. Interestingly, 
however, bands B and C could not be isolated as described above even after several large scale 
trials. This result was consistent with the western-blot competition assay. Possible reasons for 
this are (a) the proteins were bound by FP-PEG-biotin non-covalently, and were washed off by 
the buffer after the FP probe was linked to streptavidin and (b) the expressed quantities of bands 
B and C were too low to be observed on SDS-PAGE after isolation (although unlikely 
considering the strength of the fluorescence signal in the competition assay).  
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Band B and C was excised from the gel directly without serine hydrolase isolation and analyzed 
by LC/MS as a mixture of different proteins. No serine hydrolases around 30 kD were detected 
from bands B and C.  
Kinetic Mechanism of FP competition with enzymatic substrate 
Since CES1 has already been reported as an activating enzyme of oseltamivir,
17
  it is thus a more 
attractive and feasible target for the mechanism-based study of the enzymatic competition 
kinetics between oseltamivir and FP-PEG-rh. Parameters of KM and Vmax were determined by the 
hydrolysis study of oseltamivir in pure recombinant hCES1 (160 nM; Corning
®
, Tewksbury, 
MA). The hydrolysis rate was plotted as a function of substrate concentrations (0.2 - 5 mM) and 
non-linearly fitted to Michealis-Menten equation by GraphPad Prism 6 (Figure 3.4). The KM and 
Vmax values are 2.984 mM and 7.204 µM/min, respectively. The calculated kcat / KM value is 
251.34 s
-1
·M
-1
.  
The pseudo-first-order rate constant (kobs) of FP-PEG-rh (1 µM) to CES1 was determined on-gel 
based on the fluorescent signals over different time points (Figure 3.5a). The binding rate 
demonstrated from the gel is very fast such that a strong fluorescent signal could be observed 5 
sec after the initiation of the reaction and the inactivation reached essential completion after 30 
sec. However, the fast binding from FP-PEG-rh alone could be impacted by the competition of 
oseltamivir. At the same condition when CES1 (100 nM) was preincubated with oseltamivir (10 
mM) for 8 min, followed by the initiation of reaction with FP-PEG-rh (1 µM), the complete 
binding of the probe to CES1 was reached at 2 min (Figure 3.5b). The competition signals at the 
first several time points were also clearly observable from the comparison with the 
corresponding time points of FP-PEG-rh binding.  
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Fluorescence intensities from on-gel study were quantified and normalized by the average of 
their highest intensities. The fractionated intensities were then plotted exponentially over time as 
shown in figure 3.6 (kobs(s) are represented as K in the figure). The apparent binding rate of FP-
PEG-rh (kobs) is reduced by about 4-fold due to the competition of oseltamivir (k’obs).  
The calculated inactivation rate (kobs/[I]) of FP-PEG-rh is 4.0 x 10
6
 s
-1
·M
-1
, which is about 
10,000-fold faster than the turnover rate of oseltamivir (kcat/KM = 251.34 s
-1
·M
-1
). By using 10 
mM of prodrug to compete with 1 µM of FP-PEG-rh, the binding rate (kobs) was decreased by 4-
fold, to an observable time frame. 
Generally, oseltamivir binding enzymes were broadly surveyed among the serine hydrolases in 
Caco-2 whole cell proteome samples with the kinetically tuned competitive ABPP approach. The 
specific enzyme kinetics study on CES1 unveiled the fact that the covalent binding of FP probe 
could be slowed down through interference of reversible substrates. The competitive binding 
signal could only be observed within a short time frame, which is determined by the parameters 
of the applied probes (KI and kinact) and prodrugs (KM). In on-gel competition assays, the 
competitive binding rate (k’obs) of the probe could further be reduced by either decreasing probe 
concentration or increasing substrate concentration as shown in our case. This validated 
approach can potentially be applied to the detection of competitive binding between prodrugs 
and corresponding probes; in addition, confirmation of enzymatic activations have to be verified 
in follow up experiments with specific binding enzymes in over-expressed form. 
3.3 Discussion 
Identifying prodrug-activating enzymes is essential to understanding the factors that contribute to 
drug delivery and drug efficacy, yet this analysis tends to occur at a later stage or as an 
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afterthought in the drug development process. This lag is partly a result of the typically late stage 
implementation of prodrug moieties to modify biopharmaceutical properties and the time-
consuming biochemical separations and assays required for validation. In this chapter, we have 
adopted ABPP to compete the chemical probes and prodrugs toward identifying potential 
prodrug activating enzymes. This method combined tuned kinetic competition studies with LC-
MS protein identification to identify several oseltamivir binding enzymes. Despite the utility of 
the method, the competition between probes and substrates with high enzymatic turnover rate has 
some limitations: (i) a short incubation time with the probe can obscure low expressing proteins 
compared to background (ii) a long time incubation with probe can lead to complete probe 
binding to hydrolyzing enzymes, thus completely abolishing the competition signal. These 
limitations can be overcome by an in-gel competitive kinetic study, which involves screening 
with different incubation times and probe concentrations.  
This method can also be applied to activating mechanism studies of prodrugs with a selective 
activation function. Since different tissues show different degrees of serine hydrolase 
expression,
12
  SHs are expected to exist at higher levels in some tissues and lower in others.  In 
this case, a given SH may potentially be targeted for selective hydrolysis of prodrugs in a 
specific tissue. Dozens of new chemical probes targeting most of the metabolizing enzymes have 
been developed over the last ten years, which enables most of the prodrug activating enzymes to 
be associated with a functional proteomic probe. Thus, researchers have the possibility of 
choosing the right probe for the study of corresponding types of prodrugs activation. 
In summary, we have validated a rapid and practical method for the identification of potential 
prodrug activating enzymes through activity-based protein profiling competition between FP-
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PEG-rh and oseltamivir. The strategy outlined here has the advantage of surveying almost the 
entire class of serine hydrolase enzymes and could potentially accelerate process of identifying 
prodrug activating enzymes. 
3.4 Experimental Methods 
Materials 
Oseltamivir phosphate (Osel.) was purchased from Allichem LLC. Enalapril maleate salt was 
purchased from Sigma-Aldrich. Tazarotene and benazepril HCl were purchased from 
Selleckchem. FP-PEG-rhodamine was prepared as previously described.
11
  
Prodrug hydrolysis assay 
Caco-2 cytosolic and membrane fractions (2 mg/mL) in 50 mM Tris buffer (pH 7.6) were treated 
with DMSO (0.5%) as control, FP-PEG-rhodamine (5 μM) for 30 min at room temperature, and 
then oseltamivir (1 mM) was added. The reactions were incubated at 37 °C for 20 min, 50 min, 
80 min and 120 min before being terminated by two volume equivalents of acetonitrile (ACN) 
with 0.1% TFA. After centrifugation at 13,200 x g for 3 min at room temperature, the 
supernatant was filtered with Microplate PVDF filter. The filtrates were analyzed by an Agilent 
1100 HPLC system. Briefly, chromatography was performed on a 4.6 x 150 mm 3.5 micron 
ZORBAX Eclipse XDB-C18 column (Agilent), and samples were eluted with an 11 min gradient 
of 2%- 90% buffer B (Buffer A: H2O with 0.1% TFA; Buffer B: ACN with 0.1% TFA). The 
percentages of products generated were calculated based on the relative areas under the curve of 
the prodrugs and products. 
Competition assays 
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Competition assays of cytosolic and membrane fractions were performed in 50 mM Tris buffer 
(pH 7.4) in a total volume of 50 μL by first incubating proteome aliquots (1 mg/mL final), osel. 
(various concentrations as noted in figures) for 10 min at room temperature. Then FP-PEG-rh (1 
μM, 0.5 μM or 0.25 μM final) was added and incubated for 1 min, 3 min, or 5 min at room 
temperature. Competition reaction was quenched by adding 5x sample loading buffer (12.5 μL), 
heated at 85 °C for 5 min, subjected to SDS-PAGE (4% - 20%, Tris-Glycine) and visualized on-
gel in a Typhoon 9200 fluorescence imager.  
Serine hydrolases isolation by streptavidin beads  
Caco-2 cytosolic fraction (2 mg/ml, 1.5 mL) was incubated with FP-PEG-biotin (10 μM final) at 
room temperature for 1 h with occasional vortexing. Methanol (6 mL, 4 volumes) was added and 
vortexing, followed by the addition of chloroform (2.25 mL, 1.5 volumes) and vortexing, and 
then the addition of water (4.5 mL, 3 volumes) and vortexing to homogeneity. The mixture was 
centrifuged (10,000 x g) at room temperature for 10 min in a swinging bucket rotor to separate 
the aqueous and organic phases. The top aqueous phase was carefully removed and discarded 
and then 3 volumes of methanol (4.5 mL) were added and mixed gently, trying not to completely 
disrupt the pancake-like protein interface. The protein precipitate was centrifuged (10,000 x g, 2 
min) and the liquid was removed. The resulting protein precipitate was mixed with 4 volumes of 
methanol (6 mL) and sonicated at 4 °C until homogenous. The protein precipitate was 
centrifuged (10,000 x g, 10 min) and air dried for 2-3 min after removing the methanol. The 
resulting protein was resuspended in 500 μL of 6M urea / 25 mM NH4CO3H buffer, with the 
addition of 140 μL of 10% SDS, and was incubated at 65 °C for 5 min to re-solubilize protein. 
The protein solution was diluted with 6.5 mL PBS buffer and cooled to room temperature. 
Strepavidin agarose resin (Thermo Scientific, 50% slurry, 200 μL) was added and the mixture 
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incubated at room temperature for 1.5 h with rotation. The resin was centrifuged (3,000 x g, 2 
min) to a pellet and the supernatant was removed. The resin was then washed three times each by 
1% SDS in PBS buffer (200 μL) and in PBS buffer only (200 μL), respectively by vortexing, 
centrifuging, and removing supernatant. After washing buffer was removed, sample loading 
buffer (2x, 50 μL) was added to the resin and the mixture was boiled at 85 °C for 5 min. The 
resulting solution was loaded to SDS-PAGE and separated, and the corresponding protein bands 
were excised and identified by LC/MS. 
Enzymatic kinetics study on CES1 
Recombinant pure human carboxylesterase 1 (6.25 mg/L, 100 nM) was incubated with 
oseltamivir (10 min) or vehicle for 8 min at room temperature in TBS-F127 buffer (50mM Tris, 
150mM NaCl, 0.5g/L Pluronic F127, pH 7.4), followed by the addition of FP-PEG-rh (1 µM) 
with vortex. At the indicated time points, 20 µL of reaction mixture was taken and inactivated 
with 5 µL of 5 x Laemmli sample buffer, heated at 95ºC, for 5 min. Mixtures were separated by 
15% of 1:29 bis:mono acrylamide SDS gel (Figure b1, 1 ug protein/lane) and 4%-20% precasted 
Tris-Glycine gel (Invitrogen; Figure b2, 1.5 ug protein/lane). Fluoroescence intensity was 
quantified with ImageJ. 
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3.5 Figures 
 
Figure 3.1. Inhibition of oseltamivir hydrolysis. The hydrolase activity in Caco-2  cells was 
measured under the following conditions: Proteome samples (2 mg/mL, 200 μL reaction volume) 
were incubated with DMSO (control), or FP-PEG-rh (5 μM) for 30 min at room temperature and 
then with oseltamivir (1 mM) at 37 °C for 20 min, 50 min, 80 min or 120 min. The percentage of 
oseltamivir carboxylate generated in each reaction was monitored by HPLC. Results are 
represented as the average ± SEM of 2-3 individual experiments. *, p < 0.001. 
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Figure 3.2. Time vs. concentration study for oseltamivir competing with FP-PEG-rh in 
Caco-2 lysates. Caco-2 cytosolic (A) and membrane (B)  proteome samples (1 mg/mL final) 
were treated with oseltamivir (10 mM final) for 10 min at room temperature and then FP-PEG-rh 
(1 μM, 0.5 μM or 0.25 μM) for 1 min, 3 min or 5 min. Protein samples were then treated with 
sample loading buffer, heated at 85 °C for 5 min, separated by SDS-PAGE, and scanned by 
Typhoon imager. (C) Caco-2 cytosolic proteome samples (1 mg/mL) were treated with 20 mM, 
10 mM, 5 mM, 2 mM, or 0 mM of oseltamivir for 10 min and then FP-PEG-rh (0.25 μM) for 1 
min at room temperature. Protein samples were then treated with sample loading buffer, heated 
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at 85 °C for 5 min, and monitored as described above. Protein bands with the most prominent 
competition signals are labeled by red arrows as A, B, and C. 
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Figure 3.3. Serine hydrolases isolation by FP-PEG-biotin and streptavidin agarose beads. 
Lane 1 to Lane 4 were samples for competition assay to be monitored by fluorescent signal. Lane 
5 and 6 were the results from serine hydrolases isolation. Lane 7 was control group (samples 
with DMSO instead of FP-PEG-biotin). Lane 8 and 9 were competition results for comparison. 
The gel was stained by coomassie blue.  
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Figure 3.4. The hydrolysis of oseltamivir by recombinant hCES1 (a) and the determination 
of Vmax and KM by Michaelis-Menten curve (b). Oseltamivir (concentrations as noted in 
figure) was hydrolyzed in CES1 (160 nM) in Tris buffer with 1 mg/mL BSA (50 mM, pH 7.6). 
Sample was collected at each time point and analyzed by HPLC. Hydrolysis rate was calculated 
basing on the relative areas under the oseltamivir and prodruct curves. Oseltamivir hydrolysis 
rate versus oseltamivir concentration was plotted and non-linearly fitted into Michaelis - Menten 
equation by GraphPad Prism 6. Error bars represent the standard deviation of 3 individual 
experiments. 
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Figure 3.5. An on-gel comparison of CES1 binding kinetics on FP-PEG-rh alone and FP-
PEG-rh vs oseltamivir competition. rhCES1 (6.25 mg/L, 100 nM) was incubated with vehicle 
(a) or oseltamivir (b) for 8 min at room temperature in TBS-F127 buffer (50mM Tris, 150mM 
NaCl, 0.5g/L Pluronic F127, pH 7.4), followed by the addition of FP-PEG-rh (1 μM) with vortex. 
Reactions were quenched at noted time points with sample loading buffer, heated at 95 ºC for 5 
min, and through SDS-PAGE gel (1,1ug protein/lane,15% of 1:29 bis:mono acrylamide. 2, 1.5ug 
protein/lane, 4%-20% precasted Tris-Glycine gel, Invitrogen). Experiments were repeated as two 
individual SDS-PAGE gels as shown. 
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Figure 3.6. Pseudo-first-order curves for CES1binding by FP alone and oseltamivir-FP 
competition. Rate constant (kobs and k’obs) are represented as K in the figure.  
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Table 3.1. List of Possible Serine Hydrolases Identified in Caco-1 Cytosol Fraction Proteome by LC/MS-MS 
Protein ID Gene 
Name 
Discription Confidence Coverage number of 
unique 
peptides 
total 
independent 
spectral 
counts 
Band A: 
sp|P23141|EST1_HUMAN CES1 Liver Carboxylesterase 1 1.00 69.0% 56 232 
sp|O00748|EST2_HUMAN CES2 Carboxylesterase 2 1.00 24.5% 10 16 
Band B:       
sp|P27348|1433T_HUMAN YWHAQ 14-3-3 protein theta 1.00 48.2% 11 17 
sp|P18669|PGAM1_HUMAN PGAM1 Phosphoglycerate mutase 1 1.00 47.2% 11 16 
sp|P78417|GSTO1_HUMAN GSTO1 Glutathione S-transferase omega-1 1.00 24.5% 5 14 
Band C:       
sp|P60174|TPIS_HUMAN TPI1 Triosephosphate isomerase isoform 2 1.00 75.5% 24 98 
sp|P30041|PRDX6_HUMAN PRDX6 Peroxiredoxin-6 1.00 53.6% 19 47 
sp|O43399|TPD54_HUMAN TPD52L2 Tumor protein D54 1.00 41.3% 7 10 
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Chapter 4 
CHARACTERIZATION OF WWL50 AS A SELECTIVE HUMAN 
CARBOXYLESTERASE 1 INHIBITOR AND ITS UTILIZATION AGAINST GENERAL 
ESTER PRODRUGS 
4.1 Introduction 
Human carboxylesterase 1 (hCES1) is a broad-spectrum esterase with the function of xenobiotics 
detoxification, prodrugs activation as well as involvement in additional biological processes.
1
  
Analysis of the hCES1crystal structure with different therapeutic agents has provided mechanism 
information on its catalytic capability toward various substrates.
2
  This enzyme exits as a trimer 
and its active site possesses a catalytic triad of Ser221-His468-Glu354 on a monomer in a 
hydrophobic pocket at the interface of three domains, which are the catalytic regulatory and α/β 
domains. As a serine hydrolase, a two-step hydrolysis mechanism has been proposed involving 
the formation of a covalent acyl intermediate at the active serine residue, followed by subsequent 
hydrolysis and release. 
CES1 is widely distributed among different tissues such as intestine, kidney, lung, and testes but 
is mainly expressed in liver. The hydrolysis of esters with small alcohol groups and large acyl 
groups is preferred, which differs from hCES2. Due to its important role in metabolism and its 
broad-spectrum substrate properties, multiple drug-drug interactions have been observed among 
the prodrug activation, drug metabolism and in vivo hydrolysis coupled with endogenous 
55 
 
biological processes.
3
  CES1 is known to be an endogenous detoxifying enzyme, and there’s 
increasing evidence pointing to its activity contributing to obesity and diabetes.
5, 6
  Thus, the 
development of selective inhibitors or chemical probes will significantly aid in the understanding 
of drug metabolizing and disease-related functions of CES1. 
CES1 can be efficiently inhibited non-specifically by many compounds such as bis-(4-
nitrophenyl) phosphate (BNPP), phenylmethanesulfonyl fluoride (PMSF), and 4-(2-aminoethyl) 
benzenesulfonyl fluoride hydrochloride (ABESF).
4, 7
  High-throughput screening and structure-
activity relationships have been performed to discover specific inhibitors of CES1.
8, 9
  A 
selective CES1 inhibitor derived from a natural product, FR182877, has also been characterized 
by the competitive ABPP approach.
10
  In this chapter, a carbamate compound inhibiting mouse 
carboxylesterases, WWL50, was profiled against hCES1 utilizing competitive ABPP and ABPP-
SILAC approaches toward the determining CES1’s contribution to the hydrolysis of ester 
prodrugs. 
Carbamates have been reported as privileged scaffolds that covalently inhibit SHs.
11
  Their 
reactivity is associated with a tempered electrophilicity and hydrolytic stability. Several 
carbamates targeting different SHs have been developed as inhibitors, for example, UBR597 for 
FAAH
12
 and JZL184 for MAGL
13
. A carbamate library (>140) was developed by the Cravatt 
group and screened individually against a library of mouse SHs
11
. From these results, we 
selected two compounds, 4-fluoro-3-methylphenyl cyclohexylcarbamate (WWL50) and phenyl 
(3-morpholinopropyl)carbamate (WWL79) (Figure 1) for our studies based on the fact that they 
show the fewest off-target effects amongst the mouse Ces1 inhibitors. In the screening against 
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more than 200 serine hydrolases in Caco-2 cell homogenates, facilitated by ABPP-SILAC, 
WWL50 was shown to be a selective inhibitor of CES1. 
Competitive ABPP with stable isotope labeling of amino acids in cell culture (ABPP-SILAC) is 
a recently developed quantitative MS-based platform for identification of activity-based probe 
targeted enzymes
14, 15
 and selectivity profiling of small-molecule inhibitors.
16, 17
   This 
technology utilizes proteome samples from the same cell line which are treated separately with 
normal amino acid “LIGHT samples” and isotopically labeled amino acid “HEAVY samples”. 
Samples are then mixed and detected together with LC-LC/MS, which minimizes the signal 
intensity differences caused by the environmental variations. By comparison of the same protein 
from LIGHT and HEAVY samples, qualification and quantification results with greater accuracy 
can be obtained. The advantage of this approach is the application of mass spectrometry, 
enabling the profiling of a large number of enzymes (even with very low expression levels). Here 
we successfully confirm that CES1 is the primary activating enzyme of ethyl esters and that it 
contributes >95% to oseltamivir hydrolysis. This was corroborated by studies with the selective 
CES1 inhibitor, WWL50, which allows us to conclude that human CES1 is the primary 
activating enzyme for ethyl ester prodrugs. 
4.2 Results 
Selectivity Characterization of CES1 Inhibitors 
Potency and selectivity of WWL50 and WWL79 (Figure 4.1) against CES1 was demonstrated by 
competitive ABPP on SDS-PAGE. The Caco-2 cytosolic and membrane fractions were 
pretreated with the carbamates at room temperature, followed by the incubation with FP-PEG-rh 
and FP-rh. Enzymes inhibited by the inhibitors gave reduced fluorescence signals. We 
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determined that WWL50 very selectively inhibited CES1 in Caco-2 lysates, competing either 
with FP-PEG-rh (Figure 4.2A) or FP-rh (Figure 4.2B), while no other SHs showed any inhibition 
effects. On the other hand, WWL79 displayed no inhibition toward any observable SHs in 
competitive ABPP. Due to the fact that the CES2 expression level in Caco-2 cells is small and its 
on-gel fluorescence signal could overlap with CES1, we then characterized the WWL50 
selectivity with pure human recombinant CES1 and CES2. An ethyl ester prodrug, benazepril, 
was used as CES1 substrate with 4-nitrophenol acetate as a CES2 substrate. The hydrolyzed 
products were monitored by HPLC with or without inhibitor. As shown in figure 4.3, the IC50s of 
WWL50 against recombinant hCES1 and hCES2 have about a 100 fold difference. Thus, we can 
conclude that WWL50 is selective for human CES1 inhibitor amongst SHs.  
Inspired by the selectivity of WWL50, we further explored its potency against CES1. WWL50 
with different concentrations was reacted with Caco-2 cytosolic fraction and then competed with 
the FP-PEG-rh probe in a competitive ABPP assay. As demonstrated on-gel, the IC50 of WWL50 
against CES1 (~64 kD) in total cell homogenate is 2-4 μM without inhibiting any other 
observable SHs (Figure 4.4).  
ABPP-SILAC 
To identify other low level enzymes that are unobservable on-gel, we used an advanced 
quantitative MS-based platform termed ‘competitive ABPP with stable isotope labeling by 
amino acids in cell culture (ABPP-SILAC)’.14  This has been used to accurately identify and 
quantify the profile of small molecule inhibited enzymes. 
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Briefly, Caco-2 cell was cultured with isotopically labeled amino acids (HEAVY cells) and 
normal amino acids (LIGHT cells). The HEAVY and LIGHT cells were separated into 
membrane and cytosolic fractions. Light and heavy fractions were treated with WWL50 or 
vehicle, respectively, and then treated with FP-PEG-biotin. Samples were then mixed in a 1:1 
ratio, enriched with streptavidin, digested on-bead with trypsin and analyzed by NanoAcquity 
UPLC system using Synapt G2-S mass-spectrometer enabled with ion-mobility. Heavey and 
light peptide data was compiled and analyzed by the ProteinLynx Global Server 3.0. Amongst 
approximately 200 quantified serine hydrolases of the ABPP-SILAC study, of which 45 were 
represented, only CES1 and CES1P were significantly inhibited by WWL50 in Caco-2 cell 
(Figure 4.5).  
The carboxylesterase 1 pseudogene 1 (CES1P1, a.k.a CES4) is a pseudogene of CES1 with a 
premature stop codon in exon 6
18
. CES1 and CES1P1 genes are located inversely on 
chromosome 16q13-q22.1 and 28 kb apart. CES1P1 has a very high sequence similarity to CES1 
(87.7% as shown on figure 4.6) and is believed to be its inverted duplication
19, 20
. Currently 
CES1P1 has only been characterized by DNA and mRNA sequences, and its mRNA has been 
usually detected in multiple tissues together with CES1
21-23
. However there are no published 
reports of its recombinant over-expression to address its functional enzyme activity. Inferred 
amino acid sequence of CES1P1 (30.7 kDa) indicates that it is a truncated protein that resembles 
the N-terminal half of CES1. This (half) of the CES1 sequence possesses only one of the three 
catalytic triad amino acids. No inhibition by WWL50 could be observed from the on-gel 
competition studies, indicating its overlap with other protein bands and its low expression in 
Caco-2 cell (Figure 4.2, 4.4). No clear evidence from our LC-LC/MS study was able to exclude 
the possibility that the specific CES1P1 peptides our quantification relied on are from the variant 
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of a corresponding CES1mutation. Although our results indicate that CES1P1 binds to and 
potentially is reactive with the inhibitor WWL50, the functional expression and activity of 
CES1P1 need to be further investigated. Its activity, if any, against the hydrolysis of oseltamivir 
in this case could be negligible considering its low expression. For this report we conclude that 
WWL50 is a very selective human CES1 inhibitor.  
Oseltamivir Hydrolysis Inhibition by WWL50 and 79 
WWL50 and WWL79 were then applied to the hydrolysis of oseltamivir in Caco-2 lysates. As 
illustrated in figure 4.7, both FP-PEG-rh and WWL50 inhibited oseltamivir hydrolysis >95%, 
with WWL79 showing partial inhibition, approximately 20% in cytosolic and 25% in membrane 
fractions. Collectively, these data lead to the conclusion that CES1 is the primary oseltamivir 
activating enzyme, contributing >95% in the Caco-2 cell line, and that WWL50 is a selective 
inhibitor of human CES1 in Caco-2 lysates.  
Hydrolysis of Oseltamivir in Hep G2 Cell Lysates  
We extended our study from Caco-2 to the human liver carcinoma cell line (Hep G2) in an 
attempt to broaden the range of substrate hydrolases. Again we started with the hydrolysis assay 
of oseltamivir, either in the presence or absence of the FP probe and WWL50 (Figure 4.8A). 
Similar results were generated for Hep G2 as for the Caco-2 cell line with >95% of oseltamivir 
hydrolysis inhibited by WWL50 and FP-PEG-rh. Competitive ABPP was then performed 
between WWL50 and FP-PEG-rh or FP-rh to determine the selectivity of WWL50 in Hep G2 
lysates (Figure 4.8B). The results showed that WWL50 was selective against CES1 to an 
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observable extent in Hep G2 lysates. Oseltamivir was competed with FP-PEG-rh, which showed 
a reduced fluorescent signal in the CES1 band on SDS-PAGE (Figure 4.9). 
Hydrolysis Studies on Other Ethyl Ester Prodrugs 
Enalapril, benazepril, and tazarotene were chosen as examples of other ethyl ester prodrugs to 
evaluate. Valacyclovir with a valine ester pro-moiety was used as a negative control. The 
hydrolysis of these prodrugs in Hep G2 lysates, either in the presence or absence of WWL50, is 
shown in Figures 4.10A and 4.10B. The hydrolysis of all tested prodrugs was inhibited by 
WWL50, indicating that CES1 is the primary activating enzyme, although its catalyzing 
capability varies amongst substrate drugs. 
4.3 Discussion 
In this chapter, we characterized a selective CES1 inhibitor, WWL50, with which the hydrolysis 
contribution of CES1 against several ethyl ester prodrugs was determined. Theoretically, we 
could have recombinantly over-expressed all targeted oseltamivir binding enzymes in 
competitive ABPP, and tested them against oseltamivir individually to confirm their activation. 
However the discovery of WWL50 as a selective CES1 inhibitor significantly accelerates this 
process. After determining that CES1 accounts for >95% of the total hydrolysis activity, the 
activities of other non-specific binding enzymes can mostly be excluded from the activation of 
oseltamivir. The reason we did not assign 100% of hydrolysis activity to CES1 is that the 
hydrolysis of a prodrug is always a combination of chemical and enzymatic effects. We could 
always observe 1-2% more hydrolysis in cell lysates than in Tris buffer based on a previous 
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study, which may result from general acid-base catalysis by amino acid residues in the proteome 
sample. 
CES1 is an important metabolizing enzyme with various substrates. CES1 was found to be more 
active in adipose tissue from humans with obesity and diabetes.
23
  Inhibition of mouse Ces3, the 
ortholog of human CES1, can significantly increase insulin sensitivity and glucose tolerance, and 
alleviate the disease-related syndromes in the mouse model.
6
  WWL50, easily synthesized, is 
useful in the study of CES1 related catalyzing pathways in human cells. With regard to the 
characterization of the CES1 inhibitor WWL50, it is selective towards CES1 in Caco-2 and Hep 
G2 cell lines according to on-gel and competitive ABPP-SILAC study. For many of the oral 
ethyl ester prodrugs (except for those selectively activated), activation occurs mainly in the 
intestine and liver. We believe that our studies on WWL50 will facilitate mechanistic studies on 
ethyl ester prodrugs and any other ester prodrugs that are likely to be hydrolyzed by CES1 due to 
WWL50’s potency and selectivity for CES1 in Caco-2 and Hep G2 cell lines.  
In summary, using advanced ABPP-SILAC technology, we have characterized WWL50 as a 
selective inhibitor of carboxylesterase 1 among the serine hydrolases in Caco-2 and Hep G2 
human cell lines. Carboxylesterase 1 at the same time was determined as the principal activating 
enzyme, accounting for >95% of the ethyl ester prodrug hydrolase activity. We believe that 
WWL50 will facilitate the determination of CES1 related catalysis and have general utility in the 
study of other prodrug activating enzymes. 
4.4 Experimental Methods 
Materials. 
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Oseltamivir phosphate (Allichem LLC), enalapril maleate salt (Sigma-Aldrich), tazarotene 
(Selleckchem), benazepril HCl (Selleckchem), human carboxylesterase 1b (Sigma), and 
carboxylesterase 2 (Sigma) were purchased from commercial sources. FP-PEG-rhodamine, FP-
PEG-biotin and FP-rhodamine were prepared as previously described
24, 25
 
Competition assays 
Inhibitor selectivity was examined using the same method above with different concentrations 
and incubation times. Briefly, proteome samples was diluted with 50 mM Tris buffer to 1 mg/mL 
and incubated with WWL79 and WWL50 at varying concentrations (as noted in figures) for 30 
min at room temperature before the addition of FP-PEG-rhodamine (4 μM) in a 50-μL volume 
reaction. After 30 min at room temperature, the reaction was terminated by adding 5x sample 
loading buffer, heated, separated in SDS-PAGE and visualized on a Typhoon imager. 
Competitive ABPP-SILAC study 
Caco-2 was grown in SILAC-DMEM containing 100 μg/ml of 12C6 
14
N2-lysine and 
12
C6 
14
N4-
arginine (light condition) and 
13
C6 
15
N2-lysine and 
13
C6 
15
N4-arginine (heavy condition), 10% 
dialyzed FBS, and 1x penicillin/streptomycin in 100 mm tissue culture dishes in an atmosphere 
of 5% CO2 at 37 °C. The cells were grown until 13-14 days post-confluence before harvest. 
Preparation of proteome sample follows the procedure described previously.  
Proteome samples were adjusted to final protein concentration of 1.5 mg/mL. Light and heavy 
fractions (1.5 mL each) were incubated with WWL50 (15 μM) and vehicle respectively for 30 
min at room temperature. Then FP-PEG-biotin (7.5 μM) was added and reacted with rotation at 
room temperature for 1 h. After incubation, light and heavy proteomes were mixed in a 1:1 ratio. 
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Methanol (6 mL, 4 volumes) was added and vortexing, followed by the addition of chloroform 
(2.25 mL, 1.5 volumes) and vortexing, and then the addition of water (4.5 mL, 3 volumes) and 
vortexing to homogeneity. The mixture was centrifuged (10,000 x g) at room temperature for 10 
min in a swinging bucket rotor to separate the aqueous and organic phases. The top aqueous 
phase was carefully removed and discarded and then 3 volumes of methanol (4.5 mL) were 
added and mixed gently, trying not to completely disrupt the pancake-like protein interface. The 
protein precipitate was centrifuged (10,000 x g, 10 min) and the liquid was removed. The 
resulting protein precipitate was mixed with 4 volumes of methanol (6 mL) and sonicated at 4 °C 
until homogenous. The protein precipitate was centrifuged (10,000 x g, 10 min) and air dried for 
2-3 min after removing the methanol. The resulting protein was re-solubilized  in 500 μL of 6M 
urea / 50 mM ammonium bicarbonate buffer, then reduced by DTT (10 mM, 65 °C , 15 min) and 
alkyated by iodoacetamide (40 mM, room temperature, 30 min, in dark) with rotation. Then with 
the addition of 140 μL of 10% SDS, the proteome mixture was incubated at 65 °C for 10 min. 
The protein solution was diluted with 5.5 mL of PBS buffer and cooled to room temperature. 
Strepavidin agarose resin (Thermo Scientific, 50% slurry, 200 μL) was added and the mixture 
incubated at room temperature for 1.5 h with rotation. The resin was centrifuged (3,000 x g, 2 
min) to a pellet and the supernatant was removed. The resin was then washed three times each by 
1% SDS in PBS buffer (200 μL) and PBS buffer (200 μL), respectively. On-bead digestion was 
performed for 12 h at 37 °C with trypsin (Promega) in the presence of CaCl2 (2 mM). Peptide 
samples were acidified to a final concentration of 5% (v/v) formic acid and run in triplicate on 
the Waters® NanoAcquity UPLC system in 1D mode. The samples were further analyzed on the 
Waters ® Synapt G2-S mass-spectrometer enabled with ion-mobility (HDMSE).  
General synthetic methods.  
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1
H and 
13
C NMR spectra were obtained on Bruker 300 or Bruker 500 MHz spectrometers with 
CDCl3 as solvent, and chemical shifts are reported relative to the residual solvent peak in δ 
(ppm). Mass spectrometry analysis was performed by using a Waters LCT time-of-flight mass 
spectrometry instrument. Flash column chromatography was performed with silica gel (220–240 
mesh). Thin-layer chromatography (TLC) was performed on silica gel GHLF plates (250 
microns) purchased from Analtech. Developed TLC plates were visualized with a UV lamp at 
254 nm or by iodine staining. Extraction solutions were dried over MgSO4 prior to 
concentration.WWL79 and WWL50 were synthesized as previously described
11
.  
WWL79. A mixture of phenol (94.11 mg, 1 mmol), N,N’-disuccinimidyl carbonate (256.17 mg, 
1 mmol), triethylamine (140 μL, 10 mmol) and acetonitrile (4 mL) was stirred at room 
temperature for 4 h. The reaction mixture was diluted with ethyl acetate and washed sequentially 
with 0.5% aqueous HCl and brine. Following drying and concentration of the organic phase, 
compound 2 was isolated and used directly without further purification. A mixture of compound 
2 (235.05 mg, 1 mmol), 3-morpholinopropylamine (146.1 μL, 1 mmol), triethylamine (140 μL, 
10 mmol) and dichloromethane (2 mL) was stirred at room temperature for 8 h. The mixture was 
distributed between dichloromethane and water, and the organic phase dried over 
MgSO4.Concentration provided a residue which was purified by flash silica gel chromatography, 
eluting with dichloromethane/methanol (98:2). Product fractions were pooled and concentrated 
to leave pure WWL79 (211 mg) as a white powder: 
1
H NMR (400 MHz, CDCl3) δ 7.33 (m, 2 H), 
7.16-7.09 (m, 3 H), 3.71 (t, J = 7 Hz, 4 H), 3.32 (dd, J = 7 Hz, J = 13 Hz, 2 H), 2.46-2.43 (m, 6 
H), 1.74-1.68 (m, 2 H). 
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WWL50. A solution of cyclohexyl isocyanate (100 μL, 0.78 mmol), 4-fluoro-3-methylphenol 
(87.1 μL, 0.78 mmol), triethylamine (100 μL, 7.1 mmol) and toluene (5 mL) was refluxed 
overnight. Concentration of the reaction mixture gave a pale solid powder, which was purified by 
flash silica gel chromatography eluting with hexane/ethyl acetate (10:1).  Product fractions were 
pooled and concentrated to leave pure WWL50 (175.7 mg) as a white powder: 
1
H NMR (400 
MHz, CDCl3) δ 6.98-6.6.82 (m, 3 H), 4.87 (b, 1 H), 3.51 (m, 1 H), 2.25 (s, 3 H), 2.00 (m, 2 H), 
1.74 (m, 2 H), 1.62 (m, 1 H), 1.39-1.29 (m, 2 H), 1.21 (m, 3 H). 
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4.5 Figures 
 
Figure 4.1. Structures of WWL50 and WWL79 
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Figure 4.2. Competition of WWL50 and WWL79 against FP-PEG-rh and FP-rh. Proteome 
samples were treated with WWL50 or WWL79 (10 and 20 μM) for 30 min and then with FP-
PEG-rh (4 μM) (A) or FP-rh (4 μM) (B) for 30 min. Proteome samples were then treated with 
sample loading buffer, heated at 85 °C for 5 min, and analyzed by SDS-PAGE. Results indicated 
that WWL50 is selective against CES1 in Caco-2 cytosolic and membrane fractions while 
WWL79 did not show any activity. 
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Figure 4.3. Selectivity study between pure human CES1 (isoform b) and human CES2. Pure 
human recombinant carboxylesterase 1b (500 ng/mL) and carboxylesterase 2 (500 ng/mL) in 
Tris buffer with 1 mg/mL BSA (50 mM, pH 7.4) were treated with WWL50 and DMSO (as 
control) for 20 min at room temperature, followed by the addition of benazepril for CES1 and p-
nitrophenol acetate for CES2, respectively. Hydrolysis products were monitored by HPLC. 
Results are represented as the average inhibitor/vehicle ratios of 3-4 individual experiments. 
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Figure 4.4. Inhibition potency determination of WWL50 on-gel in Caco-2 cell homogenate. 
Caco-2 homogenate (cytosol fraction, 1 mg/mL) was treated with WWL50 (concentration as 
noted in figure) for 30 min at room temperature, followed by the incubation of FP-PEG-rh (4 µM) 
for another 30 min at room temperature. Reactions were terminated by 5x sample loading buffer, 
heated at 85 °C for 5 min, separated by SDS-PAGE (4 - 20 % tris-glycine, Invitrogen), and 
visualized on fluorescence scanner. 
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Figure 4.5. Selectivity characterization for WWL50 in human Caco-2 cells by ABPP-
SILAC. Bars represent means ±s.e.m. of inhibitor/vehicle ratios of identified tryptic peptides in 
both soluble and membrane proteomes for two independent biological replicates. Analysis was 
performed in separate 90-min LC-MS gradients. 45 hydrolases were selected as representatives. 
 
 
P
P
M
E
1 
0.0 
0.2 
0.4 
0.6 
0.8 
1.0 
1.2 
1.4 
H
D
H
D
3 
N
C
E
H
1 
S
IA
E
 
IA
H
1 
P
S
B
5 
P
S
B
2 
E
S
TD
 
P
S
B
1 
R
B
B
P
9 
P
P
G
B
 
P
C
P 
A
C
P
H
 
LY
P
L1
 
P
P
C
E
 
PA
1B
3 
LI
P
C
 
A
B
H
D
A 
D
P
P
4 
D
P
P
8 
O
V
C
A
2 
FA
S
 
PA
FA
2 
A
C
O
T1
 
PA
1B
2 
LY
PA
1 
A
C
O
T2
 
C
P
V
L 
D
P
P
9 
K
FA
 
A
B
H
D
B
 
LY
PA
2 
A
A
A
D
 
S
E
R
P
H
 
M
G
LL
 
A
C
O
T4
 
X
P
P
1 
P
P
C
E
L 
A
B
H
D
6 
E
S
T2
 
C
E
S
1P
 
E
S
T1
 
Serine Hydrolase
En
ric
hm
en
t R
at
io
 (W
W
L5
0 
/ D
M
SO
)
71 
 
 
Figure 4.6. Sequence alignment of CES1 and CES1P1. Protein sequence information was 
derived from Uniprot and aligned by Clustal Omega. Amino acid residues highlighted in yellow 
represent the catalytic triad of CES1. 
 
  
sp|P23141|EST1_HUMAN      MWLRAFILATLSASAAW-GHPSSPPVVDTVHGKVLGKFVSLEGFAQPVAIFLGIPFAKPP 
sp|Q9UKY3|CES1P_HUMAN     MWLPALVLATLAASAAWAGHLSSPPLVDTLHGKVLGKFVSLEGFAQPVAVFLGIPFAKPP 
                          *** *::****:***** ** ****:***:*******************:********** 
 
sp|P23141|EST1_HUMAN      LGPLRFTPPQPAEPWSFVKNATSYPPMCTQDPKAGQLLSELFTNRKENIPLKLSEDCLYL 
sp|Q9UKY3|CES1P_HUMAN     LGPLRFTLPQPAEPWNFVKNATSYPPMFTQDPKAGQLISELFTNRKENIPLKLSEDCLYL 
                          ******* *******.*********** *********:********************** 
 
sp|P23141|EST1_HUMAN      NIYTPADLTKKNRLPVMVWIHGGGLMVGAASTYDGLALAAHENVVVVTIQYRLGIWGFFS 
sp|Q9UKY3|CES1P_HUMAN     NIYTPADLTKKNRLPVMVWIHGGGLMVGAASTYDGLALAAHENVVVVTIQYRLGIWGFFS 
                          ************************************************************ 
 
sp|P23141|EST1_HUMAN      TGDEHSRGNWGHLDQVAALRWVQDNIASFGGNPGSVTIFGESAGGESVSVLVLSPLAKNL 
sp|Q9UKY3|CES1P_HUMAN     TGDEHSPGNWGHLDQLAALHWVQDNIASFGGNPGSVTIFGGSVGGESVSVLVLSPLAKNL 
                          ****** ********:***:******************** *.***************** 
 
sp|P23141|EST1_HUMAN      FHRAISESGVALTSVLVKKGDVKPLAEQIAITAGCKTTTSAVMVHCLRQKTEEELLETTL 
sp|Q9UKY3|CES1P_HUMAN     FHRAISESGVALTSVLVKKGDVKPLAEVGLRLVRLRLDTPTSLALCS------------- 
                          ***************************     .  :  * : :. *               
 
sp|P23141|EST1_HUMAN      KMKFLSLDLQGDPRESQPLLGTVIDGMLLLKTPEELQAERNFHTVPYMVGINKQEFGWLI 
sp|Q9UKY3|CES1P_HUMAN     ------------------------------------------------------------ 
                                                                                        
 
sp|P23141|EST1_HUMAN      PMQLMSYPLSEGQLDQKTAMSLLWKSYPLVCIAKELIPEATEKYLGGTDDTVKKKDLFLD 
sp|Q9UKY3|CES1P_HUMAN     ------------------------------------------------------------ 
                                                                                        
 
sp|P23141|EST1_HUMAN      LIADVMFGVPSVIVARNHRDAGAPTYMYEFQYRPSFSSDMKPKTVIGDHGDELFSVFGAP 
sp|Q9UKY3|CES1P_HUMAN     ------------------------------------------------------------ 
                                                                                        
 
sp|P23141|EST1_HUMAN      FLKEGASEEEIRLSKMVMKFWANFARNGNPNGEGLPHWPEYNQKEGYLQIGANTQAAQKL 
sp|Q9UKY3|CES1P_HUMAN     ------------------------------------------------------------ 
                                                                                        
 
sp|P23141|EST1_HUMAN      KDKEVAFWTNLFAKKAVEKPPQTEHIEL 
sp|Q9UKY3|CES1P_HUMAN     ---------------------------- 
                                                        
72 
 
 
Figure 4.7. Inhibition of oseltamivir hydrolysis by probe and inhibitors. Caco-2 proteome 
samples (1 mg/mL) were incubated with DMSO (control), FP-PEG-rh (4 μM), WWL50 (10 μM) 
and WWL79 (10 μM), respectively, for 30 min at room temperature. Oseltamivir was then added 
followed by incubation at 37 °C. Reaction samples were collected at 20 min, 50 min, 80 min and 
120 min, and analyzed by HPLC. Results are represented as the average ± SEM of 2-3 individual 
experiments. 
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Figure 4.8. Oseltamivir hydrolysis study in Hep G2. (A) Hep G2 cytosolic (1 mg/mL) and 
membrane (1 mg/mL) fractions were treated with FP, WWL50, and oseltamivir as described 
above for Caco-2 lysates. Results are represented as the average ± SEM of 2-3 individual 
experiments. (B) Competitive ABPPs between FP-PEG-rh, FP-rh and WWL50 were performed 
as described for Caco-2 lysates. 
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Figure 4.9. Competitive ABPPs between FP-PEG-rh, and oseltamivir. Experiments were 
performed the same as described previously for Caco-2 lysates. 
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Figure 4.10. Hydrolysis of ethyl ester prodrugs in Hep G2 lysates. Enalapril (1 mM), 
benazapril (0.5 mM), tazarotene (0.25 mM) and valacyclovir (0.5 mM) were hydrolyzed at 37 °C 
in Hep G2 cytosolic (1 mg/ml) (A) and membrane (1 mg/ml) (B) proteome samples following 
preincubation with WWL50 (10 μM) and DMSO (control) for 30 min at room temperature. 
Reaction samples were collected at 10, 20, 30 and 60 min, and analyzed by HPLC. Results are 
represented as the average ± SEM of 2-3 individual experiments. 
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Scheme 4.1. Synthesis of WWL79 and WWL50. 
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Chapter 5 
SUMMARY 
Knowing the identity of select prodrug activating enzyme(s) is essential to understanding the 
mechanistic basis for enhanced cellular delivery, biodistribution, and prodrug stability. In 
addition, understanding species-specific pro-drug sensitivities is critical for evaluating pre-
clinical animal models and evaluating drug-drug interactions. Competitive Activity Based 
Protein Profiling (ABPP) describes an emerging chemoproteomic approach to assay active site 
occupancy within a mechanistically similar enzyme class within native proteomes, and has 
proven to be a powerful approach for selectivity-guided medicinal chemistry. This approach uses 
enzyme class specific reporter-linked covalent probes, such as the serine hydrolase privileged 
fluorophosphonates, for mechanism-based covalent labeling of the more than 100 serine 
hydrolases in the human genome, including a broad profiling of serine proteases, lipases, and 
thioesterases. 
In this regard, a synthetic route for a fluorophosphonate-polyethylene glycol-biotin probe was 
optimized and its capability of labeling serine hydrolases was verified in a human cell 
homogenate with an activity-based protein profiling competition between FP-PEG-rhodamine 
and oseltamivir established. Human carboxylesterase 1 was identified as an oseltamivir binding 
enzyme and WWL50 as a selective CES1 inhibitor. WWL50 selectivity was characterized and 
applied to the determination of CES1’s contribution to ester prodrug hydrolysis. 
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Chapter 2 of this thesis describes a novel synthetic route to link the FP group to a biotin tag 
through a polyethylene glycol linker to improve the original synthesis. This route markedly 
increases the efficiency of the probe synthesis and overcomes problems from a prior literature 
synthesis. Special features of the synthesis include the use of a benzyl protecting group to 
provide a UV sensitive group for the purification steps that followed, and a facile incorporation 
of an iodide group resulting in high yield of key intermediate without any flash column 
purifications. Under novel reaction conditions, lithium azide was utilized in the 
monodealkylation of a phosphonate diester. The synthesis was completed by the clean 
incorporation of the reactive fluoride group in high yield with DAST. The purity of the final 
product was established by NMR, and the compound was then directly used in biological tests.  
The Activity-Based Protein Profiling (ABPP) approach for the determination of functional 
enzymatic activity has been extensively developed for serine hydrolases by Cravatt et al. and 
cysteine hydrolases by Bogyo et al.  A variety of probes have been designed for various other 
enzyme classes and have been used for the characterization of selective inhibitors and enzyme 
annotations. A few reports have focused on competitive ABPP between the enzyme probe and 
enzyme substrates. In chapter 3 we describe a modified ABPP approach using direct prodrug 
competition to FP probes to identify CES1 as the one of the prodrug hydrolyzing enzymes of 
oseltamivir. We utilize the fluorophosphonate probes developed by the Cravatt group with either 
a rhodamine or a biotin tag linked to the fluorophosphonate for either on-gel visualization or 
streptavidin bead purification, respectively. When present with time and concentration optimized, 
the prodrug will reduce the probe binding to the enzyme active site and thus detect potential 
activating enzymes. The hydrolysis of oseltamivir, an ethyl ester prodrug, in a Caco-2 cell 
homogenate was inhibited by FP-PEG-rh, demonstrating that all of the potential oseltamivir 
81 
 
hydrolyzing enzymes are effectively inhibited and bound by the FP probe. A subsequent on-gel 
competition between oseltamivir and FP-PEG-rhodamine was performed with kinetically 
controlled FP concentration and incubation time. By the direct comparison of different 
competition conditions, enzyme bands with the most significant fluorescent signal differences 
were targeted as potential oseltamivir binding enzymes.  
In order to identify them, all the serine hydrolases in the Caco-2 cell homogenate were 
covalently linked by FP-PEG-biotin, and pulled down on streptavidin agarose beads by the 
strong interaction between biotin and streptavidin. The accumulated serine hydrolases were then 
separated on SDS-PAGE. A protein band observed at about 60 kDa was identified as human 
carboxylesterase 1 by LC-LC/MS. Two other protein bands at 30 kDa were excised from the gel 
and were identified as mixture of non-serine hydrolases. In this chapter, a new approach of 
identifying prodrug activating enzymes seldom discussed before was described and established 
with the hydrolysis of oseltamivir by carboxylesterase 1 as an example. The kinetic competition 
between a substrate with high enzymatic turnover rate (oseltamivir) and a covalent chemical 
probe (FP-PEG-rh) was demonstrated with different incubation times and concentrations.  
Having identified CES1 as an activating hydrolase for oseltamivir, we next determined (Chapter 
4) the level that it contributed to its hydrolysis, and which of the other binding enzymes 
identified above were also involved in the enzymatic hydrolysis. We selected two inhibitors, 
WWL50 and WWL79 as the most selective CES1 inhibitors for our studies. FP-PEG-rh was 
competed for by them to test their selectivity and potency. The on-gel competitive ABPP results 
showed no observable competition signals from WWL79 against any serine hydrolases while 
WWL50 exhibited strong inhibition activity against CES1 selectively in Caco-2 cell homogenate. 
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Determination of the IC50 of WWL50 against human CES1 and CES2 was further performed 
with the recombinantly over-expressed pure enzymes due to the low expression amount of 
hCES2 in Caco-2 cells. WWL50 is able to differentiate CES1 and CES2 by 100-fold in IC50 
values. An even larger profiling of the selectivity of WWL50 among all serine hydrolases in 
Caco-2 cells was further pursued with the ABPP-SILAC based proteomic approach. Competition 
signals from FP-PEG-biotin versus WWL50 were observed from a mixture of isotopically 
labelled and native enzymes, pointing out that WWL50 is selective against CES1 amongst more 
than 200 profiled serine hydrolases in the Caco-2 cell. The results from the hydrolysis assay 
showed total inhibition of oseltamivir hydrolysis in a Caco-2 cell homogenate by WWL50, 
which led to the conclusion that CES1 is the primary activating enzyme of oseltamivir. 
We then further tested the on-gel selectivity of WWL50 in Hep G2 cell homogenate (a cell line 
derived from human liver carcinoma) by competitive ABPP. The on-gel competition signal 
clearly indicated that WWL50 is also selective against CES1 in a Hep G2 homogenate. WWL50 
was then applied to the hydrolysis assays of oseltamivir and several other ethyl ester prodrugs in 
a Hep G2 cell homogenate, with the conclusion that CES1 is the primary activating enzyme for 
ethyl ester prodrugs mediating more than 95% of the activation. 
Overall, we present a modified substrate-competitive activity-based profiling approach for 
discovering specific prodrug hydrolyzing enzymes, which promises to be a useful methodology 
for ester prodrug design and preclinical development of ester prodrugs. The determination and 
characterization of prodrug activating enzymes and the corresponding inhibitors will 
significantly enhance our ability to unveil prodrug activation mechanisms.
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APPENDICES 
APPENDICES 1  
SYNTHESIS OF NOVEL BENZOXAZINORIFAMYCINS ANALOGUES 
A1.1 Introduction 
Tuberculosis (TB) is a contagious and deadly disease that has reached pandemic proportions. 
According to the World Health Organization (WHO), 8−10 million new cases of TB are 
diagnosed each year, making Mycobacterium tuberculosis (MTB) a leading cause of death in 
adults (2−3 million/year) due to an infectious agent.1  A high proportion of these new cases and 
deaths occur in HIV-positive people with a significant number of AIDS deaths in Africa being 
attributed to TB infections. Global population growth is increasing the disease burden, posing a 
continuing health and financial burden in various parts of the world, particularly Asia and Africa. 
TB is caused predominantly by MTB, an obligate aerobic bacillus that divides at an extremely 
slow rate. The chemical composition of its cell wall includes peptidoglycans and complex lipids, 
in particular mycolic acids, which are a significant determinant of its virulence.
2
  The unique 
structure of the cell wall of MTB allows it to lie dormant for many years as a latent infection, 
particularly as it can grow readily inside macrophages, hiding it from the host’s immune system.
The continuing rise in multidrug-resistant strains of MTB (MDR-TB) has further contributed to 
the dire need for new TB antibiotics, as no new TB drugs have been introduced into clinical use 
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in the past 4 decades.
3, 4
  Drugs that are active against resistant forms of TB are less potent, more 
toxic and need to be taken for an extended period of time (≥18 months). The recent emergence of 
virtually untreatable extensively drug-resistant TB (XDR-TB) poses a new threat to TB control 
worldwide. Furthermore, effective treatment of TB in persons co-infected with HIV is 
complicated because of drug−drug interactions. Shorter and simpler regimens that are safe, well 
tolerated, and effective against drug-susceptible and drug-resistant TB, which are appropriate for 
joint HIV-TB treatment and amenable to routine clinical settings, are needed urgently.
5, 6
 
he rifamycins are the most commonly used drugs for TB, and semisynthetic derivatives have 
been reported that show improved antimycobacterial activities.
7
 These include rifampin (1a, 
RMP, Figure A.1), which is the cornerstone of current short-term tuberculosis treatment. Among 
newer derivatives, rifalazil (2a, RLZ, Figure A.1) has proved most interesting not just because of 
its excellent potency but also because of its relative lack of toxicity in early rodent studies.
8
  RLZ 
is an exceedingly potent rifamycin derivative, being 16−256 times more potent than RMP,9-11  
and is particularly effective against many of the RMP-resistant strains of MTB.
10, 12
  Several 
studies involving strains with various rpoB mutations clearly indicated that the mutations 
identified with the RMP, rifapentine, and rifabutin resistant strains retained sensitivity to RLZ.
13, 
14
  RLZ and its benzoxazinorifamycin analogues also have showed excellent activity against 
other organisms with RMP-resistant mutations, including Streptococcus pyogenes, Chlamydia 
trachomatis, and Chlamydia pneumonia.
15, 16
  
In mouse in vivo efficacy studies, RLZ has been shown to be clearly more potent than RMP 
including activity against some RMP-resistant strains,
9, 11, 17-19
 and longer term MTB studies in 
combination with other agents indicated that the same level of cure could be achieved with 
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shorter (at least 2-fold) duration of treatment with RLZ compared to RMP.
20-22
  In 
pharmacokinetic (PK) studies, RLZ has shown a high volume of distribution and produced tissue 
levels in rats up to 200 times those in plasma. It displayed a very long half-life (60−100 h) in 
human trials.  One major downside to the rifamycins used to treat TB is their many drug−drug 
interactions. This effect appears to be diminished with RLZ, as shown in rat and the dog 
studies.
23
  This study also showed RLZ not to be an inducer of hepatic cytochrome P450 
(Cyp450). In a series of phase I
24, 25
 and phase II
9, 24-26
 clinical trials, RLZ proved to be quite 
toxic, with most adverse effects associated with a flulike syndrome and leucopenia even at lower 
dose levels. Hence, its development for TB indications has been suspended.
27
 
In this section, we detail the structure-based design, and synthesis of representative compounds 
(2b−d, Figure A.1) of a novel subclass of RLZ (2a) in which ether tethers have been installed off 
the 3’-position of the “southeastern” part of the benzoxazinorifamycin template. 
A1.2 Results and Discussion 
The synthetic route utilized to make our target “one-armed” compounds 2b−d is shown in 
scheme A.1. The RLZ literature
28
 suggested a strategy of annulating the benzoxazino moiety 
onto rifamycin S (12) with a suitably protected monoether (e.g., TBS) of 2-aminoresorcinol, 
followed by ether deprotection and then side chain installation off the nascent phenol by any 
number of alkylation methodologies. This was investigated, but yields were very poor and the 
scope of alkylation possibilities was quite limited (data not shown). We opted instead to annulate 
a fully tethered 2-aminoresorcinol monoether onto the rifamycin S framework in a single step. 
This allowed us to consider a wide range of tethers off the “southeastern” part of the rifalazil-
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type template and, more importantly, minimized difficult synthetic transformations and product 
purifications involving the complex rifamycin S core to a single last step. Thus, we set our sights 
initially on developing a robust procedure to intermediate 5, which would serve as a key starting 
material for introduction of our chosen tethers. While there are two reports for the synthesis of 
this compound,
29, 30
  neither was deemed practical for our needs. Instead, we pursued a two-step 
procedure. Accordingly, dialkylation of 2-nitroresorcinol (3), similar to the literature 
procedure,
31
  gave a 95% yield of dibenzyl ether 4 which was then cleanly monodebenzylated to 
nitrophenol 5
29
 in 82% yield. With 5 now in hand, we were ready to install our target tethers. 
Phenolic alkylation with 2-(diethylaminoethyl)-ethyl chloride hydrochloride under standard 
conditions provided 6 in 87% yield. Hydrogenation of 6 utilizing Pearlman’s catalyst 
simultaneously reduced the nitro function and hydrogenolyzed the benzyl protecting group to 
give the 2-aminoresorcinol ether 7 in 81% yield. A similar sequence of reactions was followed to 
provide ethers 11a, b. Alkylation of 5 with 1,4-dibromobutane gave 8 in 93% yield, which was 
subsequently aminated with two monosubstituted piperazines to afford compounds 9a and 9b in 
68% and 99% yields, respectively. t-Boc deprotection of 9b followed by acylation of 9c with 2-
(1H-imidazol-1-yl)acetic acid provided 10, the amide congener of 9a, in 72% yield. 
Hydrogenation of 9a and 10 was conducted as described for 6 to provide the remaining 2- 
aminoresorcinol ethers 11a and 11b, respectively, in nearly quantitative yields.  
The structure of each 2-aminoresorcinol ether (7, 11a, 11b) is supported by mass spectrometry 
along with 
1
H and 
13
C NMR spectra. Each was then annulated onto rifamycin S (12) to provide 
target compounds 2b−d in 35−74% yields following a two-stage purification utilizing medium 
pressure and then preparative plate silica gel chromatography. No effort was made to optimize 
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the condensation reaction with rifamycin S, but we feel that this has the potential to be an 
efficient transformation. 
A1.3 Experimental Methods 
All the reagents and solvents were purchased commercial chemical companies and used without 
further purification unless otherwise noted. Melting points were determined in open capillary 
tubes on a Laboratory Devices Mel-Temp apparatus and are uncorrected. 
1
H and 
13
C NMR 
spectra were obtained on Bruker 500 MHz spectrometers with CDCl3 or d6-DMSO as solvent 
and chemical shifts are reported relative to the residual solvent peak in δ (ppm).  Mass 
spectrometry analysis was performed using a Waters LCT time-of-flight mass spectrometry 
instrument. High resolution mass spectrometry (HRMS) analysis was performed on an Agilent 
Q-TOF system. Perkin Elmer Series 200 HPLC system with Agilent Eclipse plus C18 (4.6 x 7.5 
mm, 3.5 mm particle size) was used for analytical HPLC analysis. The mobile phase was a 11 
min binary gradient of acetonitrile (containing 0.1 % TFA) and water (20–90%). Extraction 
solutions were dried over MgSO4 prior to concentration. Silica Gel GHLF (250 microns), 
purchased from Analtech, was used as thin layer chromatography. 
(((2-Nitro-1,3-phenylene)bis(oxy))bis(methylene))dibenzene (4).  A mixture of 2-
nitroresorcinol (3; 2.0 g, 12.9 mmol), Cs2CO3 (10.5 g, 32.2 mmol), benzyl bromide (3.39 ml, 
28.4 mmol) and DMF (35 mL) was stirred at room temperature for 12 h. The mixture was diluted 
with ethyl acetate and washed sequentially with 1% aq HCl and brine. The organic phase was 
dried and concentrated to leave a yellow oil, which was diluted with 2-propanol to precipitate 
pure product. The solids were collected to leave 4 (4.11 g, 95%) as light yellow crystals: mp 87.5 
- 88ºC (lit
31
 80ºC); Rf  0.26 (hexanes : ethyl acetate, 5 : 1); 
1
H NMR (CDCl3)  7.3 (m, 10 H), 
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7.23 (t, J = 8.5 Hz, 1 H), 6.64 (d, J = 8.5, 2 H), 5.16 (s, 4 H); 
13
C NMR (CDCl3)  150.9, 135.6, 
130.9, 128.7, 128.2, 127.0, 106.2, 71.0; MS (ES
+
) m/z 358.1 (M+Na)
+
. 
3-(Benzyloxy)-2-nitrophenol (5).  A solution of dibenzyl ether 4 (3.0 g, 8.95 mmol) in 
dichloromethane (80 mL) at -78ºC was treated drop-wise with boron trichloride (13 mL, 1M in 
heptane) during which the color changed to dark purple. The reaction was monitored by TLC and 
stirred at -78ºC until all starting material was consumed (1 h).  Methanol (5 mL) was added drop-
wise and the mixture was brought to room temperature, cautiously diluted with 5% aq sodium 
bicarbonate, and then extracted with dichloromethane (2x).  The combined extracts were dried 
and concentrated to an orange oil that was purified by flash silica gel chromatography eluting 
with hexanes : ethyl acetate (5 : 1). Product fractions were combined and concentrated to give 5 
(1.79 g, 82%) as a bright yellow solid: mp 67 - 67.5 ºC; Rf  0.24 (hexanes : ethyl acetate, 5 : 1); 
1
H NMR (CDCl3)  10.18 (brs, 1 H), 7.4 (m, 2 H), 7.3 (m, 4 H), 6.72 (d, J = 8.5 Hz, 2 H), 6.6 (d, 
J = 8.5 Hz, 2 H), 5.21 (s, 2 H); 
13
C NMR (CDCl3)  155.7, 154.7, 135.6, 135.4, 128.7, 128.2, 
126.9, 111.0, 105.1, 71.4; MS (ES
+
) m/z 268.0 (M+Na)
+
. 
2-(3-(Benzyloxy)-2-nitrophenoxy)-N,N-diethylethanamine (6).  A mixture of nitrophenol 5 
(1.31 g, 5.4 mmol), 2-(diethylaminoethyl)ethyl chloride hydrochloride (1.2 g, 7 mmol), Cs2CO3 
(4.37 g, 13.4 mmol) and acetone (20 mL) was stirred at 50ºC for 3 h. The mixture was filtered 
and the filtrate was concentrated to a residue that purified by flash silica gel chromatography 
eluting with hexanes : ethyl acetate (5 : 1). Product fractions were combined and concentrated to 
leave 6 (1.71 g, 93%) as a light yellow oil: Rf = 0.22 (CH2Cl2 : methanol, 95 : 5); 
1
H NMR 
(CDCl3)  7.3 (m, 6 H), 6.62, (dd, J1 = 3.6 Hz, J2 = 14.1 Hz, 2 H), 5.16 (s, 2 H), 4.1 (t, J = 10.5 
Hz, 2 H), 2.8 (t, J = 10.5 Hz, 2 H), 2.6 (q, J = 11.9 Hz, 4 H), 1.0 (t, J = 11.9 Hz, 6 H); 
13
C NMR 
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(CDCl3)  151.2, 150.8, 135.6, 130.9, 128.6, 128.2, 127.0, 105.9, 105.6, 70.9, 68.5, 51.2, 47.9, 
11.9; MS (ES
+
) m/z 245.1 (M+H)
+
. 
2-Amino-3-(2-(diethylamino)ethoxy)phenol (7).  2-(Diethylamino)ethyl ether 6 (1.8 g, 5.2 
mmol) was dissolved in 10% acetic acid in methanol (50 mL) in a 250 mL Parr hydrogenation 
bottle. Catalyst (20% Pd(OH)2/C, 0.1 g) was added and the mixture was hydrogenated at 40 psi 
H2 for ~20 h. The reaction mixture was rapidly filtered over Celite®, and the filtrate was 
concentrated and diluted with ethyl acetate. The solution was washed with 5% aq sodium 
carbonate, dried, and concentrated to a brown solid that was triturated in hot hexanes.  The solids 
were collected and dried to leave 7 (0.95 g, 81%): mp 91 - 91.5ºC; Rf 0.21 (CH2Cl2 : methanol, 
85 : 15); 
1
H NMR (CDCl3)  6.55 (t, J = 7.7 Hz, 1 H), 6.4 (m, 2 H), 4.07 (t, J = 5.8 Hz, 2 H), 
2.91 (t, J = 5.8 Hz, 2 H), 2.7 (m, 4 H), 1.1 (t, J = 7.1 Hz, 6 H); 
13
C NMR (CDCl3)  148.0, 145.3, 
124.9, 117.8, 109.0, 104.4, 66.5, 51.9, 47.4, 11.1; MS (ES
+
) m/z 225.1 (M+H)
+
. 
1-(Benzyloxy)-3-(4-bromobutoxy)-2-nitrobenzene (8).  To a mixture of DMF (5 mL), 1,4-
dibromobutane (5 mL) and Cs2CO3 (1.66 g, 5.1 mmol) was added slowly a solution of 
nitrophenol 5 (0.5 g, 2.0 mmol) in DMF (5 mL). The mixture was stirred at room temperature for 
16 h, and then DMF was removed in vacuo to leave an oil that was distributed between 1% aq 
HCl and ethyl acetate. The organic phase was dried and concentrated to a light yellow oil that 
was purified by flash silica gel chromatography eluting with hexanes : ethyl acetate (6 : 1). 
Product fractions were combined and concentrated to give 8 (0.702 g, 93%) as a light yellow oil: 
Rf 0.45 (hexanes : ethyl acetate, 2 : 1); 
1
H NMR (CDCl3)  7.36 (m, 5 H), 7.26 (m, 1 H), 6.61 (m, 
2 H), 5.16 (s, 2 H), 4.08 (t, J = 5.8 Hz, 2 H), 3.46 (t, J = 6.3 Hz, 2 H), 2.02 (m, 2 H), 1.92 (m, 2 
90 
 
H); 
13
C NMR (CDCl3)  151.1, 150.9, 135.6, 131.0, 128.7, 128.2, 127.0, 106.1, 105.6, 70.9, 68.4, 
33.4, 28.9, 27.5; MS (ES
+
) m/z 401.9, 403.9 (M+Na)
+
. 
1-(2-(1H-Imidazol-1-yl)ethyl)-4-(4-(3-(benzyloxy)-2-nitrophenoxy)butyl)piperazine (9a).  A 
solution of bromobutyl ether 8 (1.0 g, 2.6 mmol), 1-[2-(1H-imidazol-1-yl)ethyl]piperazine (0.52 
g, 2.9 mmol, purchased from Oakwood Products Inc.), N,N-diisopropylethylamine (5 mL) and 
acetonitrile (18 mL) was heated at reflux overnight. The solution was concentrated and the 
residue was distributed between dichloromethane and 5% aq sodium carbonate. The organic 
phase was dried and concentrated to an orange oil that was purified by flash silica gel 
chromatography eluting with dichloromethane : methanol : NH4OH (90 : 10 : 0.5). Product 
fractions was combined and concentrated to leave 9a (0.86 g, 68%) as an oil: 
1
H NMR (CDCl3)  
7.53 (s, 1 H), 7.36-7.22 (m, 6 H), 7.03 (s, 1 H), 6.97 (d, J = 1.1 Hz, 1 H), 6.61 (m, 1 H), 5.15 (s, 
1 H), 4.05 (t, J = 6.3 Hz, 2 H), 4.01 (t, J = 6.5 Hz, 2 H), 2.67 (t, J = 6.5 Hz, 2 H), 2.48 (bs, 8 H), 
2.36 (t, J = 6.5 Hz, 2 H), 1.79 (m, 2 H), 1.61 (m, 2 H); 
13
C NMR (CDCl3)  151.3, 150.8, 137.4, 
135.6, 132.8, 130.9, 129.2, 128.7, 128.2, 127.0, 119.3, 105.8, 105.6, 70.9, 69.3, 58.6, 57.8, 53.3, 
53.0, 44.7, 26.9, 23.1; MS (ES
+
) m/z 480.1 (M+H)
+
. 
tert-Butyl 4-(4-(3-(benzyloxy)-2-nitrophenoxy)butyl)piperazine-1-carboxylate (9b).  A 
solution of bromobutyl ether 8 (0.4 g, 1.05 mmol), 1-Boc-piperazine (0.282 g, 1.514 mmol) N,N-
diisopropylethylamine (4 mL) and acetonitrile (10 mL) was heated at 80ºC for 12 h. The solution 
was concentrated and distributed between ethyl acetate and brine. The organic phase was dried 
and concentrated to residue that was purified by flash silica gel chromatography eluting with 
ethyl acetate. Product fractions were combined and concentrated to leave 9b (0.505 g, 99%): 
1
H 
NMR (CDCl3)  7.36 (m, 4H), 7.31 (m, 1 H), 7.24 (m, 1 H), 6.61 (m, 2 H), 5.16 (s, 2 H), 4.06 (t, 
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J = 6.2 Hz, 2 H), 3.41 (t, J = 7.0 Hz, 4 H), 2.36 (t, J = 7.0 Hz, 4 H), 1.80 (m, 2 H), 1.62 (m, 2 H), 
1.46 (s, 9 H), 1.26 (t, J = 7.2 Hz, 2 H); 
13
C NMR (CDCl3)  154.9, 151.5, 150.9, 135.8, 131.0, 
128.8, 128.3, 127.1, 106.0, 105.7, 79.7, 71.1, 69.4, 60.5, 58.1, 53.1, 28.6, 27.0, 23.2, 21.2, 14.3; 
MS (ES
+
) m/z 486.1 (M+H)
+
. 
1-(4-(4-(3-(Benzyloxy)-2-nitrophenoxy)butyl)piperazin-1-yl)-2-(1H-imidazol-1-yl)ethanone 
(10).  Trifluoroacetic acid (2 mL) was added dropwise to a solution of 9b (0.505 g, 1.04 mmol) 
in dichloromethane (8 mL), and the resultant mixture was stirred at room temperature for 3 h.  
The solution was concentrated to leave 9c (0.52 g, quantitative) as the crystalline trifluoroacetate 
salt.  This was then dissolved into DMF (10 mL) and N,N-diisopropylethylamine (3 mL) and the 
mixture was stirred at room temperature for 10 min followed by treatment with 1-ethyl-3-[3-
dimethylaminopropyl]carbodiimide hydrochloride (EDC·HCl; 0.22 g, 1.14 mmol), N-
hydroxybenzotriazole (HOBt; 0.175 g, 1.14 mmol) and imidazoacetic acid (0.197 g, 1.56 mmol, 
purchased from Tokyo Chemical Industry Co. Ltd.) After stirring under N2 at room temperature 
for 16 h, DMF was removed in vacuo and the residue was distributed between dichloromethane 
and 5% aq sodium carbonate. The organic phase was dried and concentrated to an oil that was 
purified by flask silica gel chromatography eluting with methanol : CH2Cl2 : NH4OH (5 : 95 : 
0.5). Product fractions were pooled and concentrated to give 10 (0.37 g, 72%) as a yellow oil: 
1
H 
NMR (CDCl3)  7.49 (s, 1 H), 7.36 (m, 5 H), 7.26 (m, 1 H), 7.09 (s, 1 H), 6.95 (s, 1 H), 6.61 (m, 
1H), 5.16 (s, 2 H), 4.75 (s, 2 H), 4.07 (t, J = 5.9 Hz, 2 H), 3.62 (m, 2 H), 3.44 (m, 2 H), 2.42 (t, J 
= 4.9 Hz, 4 H), 2.39 (t, J = 7.2 Hz, 2 H), 1.81 (m, 2 H), 1.62 (m, 2 H); 
13
C NMR (CDCl3)  164.4, 
151.3, 150.8, 138.0, 135.6, 131.0, 129.5, 128.7, 128.2, 127.0, 120.1, 105.9, 105.5, 70.9, 69.1, 
57.6, 52.6, 47.9, 45.1, 42.3, 26.7, 22.9; MS (ES
+
) m/z 494.1 (M+H)
+
.  
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3-(4-(4-(2-(1H-Imidazol-1-yl)ethyl)piperazin-1-yl)butoxy)-2-aminophenol (11a). Compound 
9a (0.86 g, 1.8 mmol) was dissolved in a mixture of 10% aq HCl (10 mL) and methanol (90 mL) 
in a Parr hydrogenation bottle. Catalyst (20% Pd(OH)2/C, 0.05 g) was added and the mixture was 
hydrogenated at 40 psi H2 for ~40 h. The reaction mixture was rapidly filtered over Celite®, and 
the filtrate was concentrated and diluted with ethyl acetate. The solution was washed with 5% aq 
sodium carbonate, dried, and concentrated to give 11a (0.61 g, 95%) as a brown solid:
 1
H NMR 
(CDCl3)  7.56 (s, 1 H), 7.05 (s, 1 H), 6.96 (s, 1 H), 6.52 (t, J = 7.2 Hz, 1 H), 6.44 (s, 1 H), 6.37 
(d, J = 8.0 Hz, 1 H), 3.98 (m, 4 H), 2.66 (t, J = 6.2 Hz, 2 H), 2.49 (bs, 8 H), 2.41 (t, J = 6.5 Hz, 2 
H), 1.78 1.68 (m, 2 H); 
13
C NMR (CDCl3)  147.6, 145.5, 128.6, 124.9, 119.4, 117.3, 108.7, 
103.7, 68.1, 58.4, 58.2, 53.0, 50.4, 44.7, 27.5, 23.3; MS (ES
+
) m/z 360.1 (M+H)
+
. 
 
1-(4-(4-(2-Amino-3-hydroxyphenoxy)butyl)piperazin-1-yl)-2-(1H-imidazol-1-yl)ethanone 
(11b).  Compound 10 (0.37 g, 0.75 mmol) was dissolved in a mixture of 10% aq HCl (5 mL) and 
methanol (45 mL) in a Parr hydrogenation bottle. Catalyst (20% Pd(OH)2/C, 0.02 g) was added 
and the mixture was hydrogenated at 40 psi H2 for ~40 h. Workup as described above for the 
synthesis of 11a gave 11b (0.27 g, 98%) as a brown solid: 
1
H NMR (CD3OD)  7.78 (s, 1 H), 
7.13 (s, 1 H), 7.06 (s, 1 H), 6.58 (m, 1 H), 6.43 (m, 2 H), 5.08 (s, 2 H), 4.03 (t, J = 5.9 Hz, 2 H), 
3.66 (s, 2 H), 3.62 (s, 2 H), 2.75 (s, 2 H), 2.65 (m, 4 H), 1.82 (m, 4 H); 
13
C NMR (CD3OD)  
174.8, 165.8, 148.0, 145.8, 138.1, 126.0, 123.0, 121.3, 118.2, 107.8, 103.5, 67.7, 57.3, 52.1, 51.8, 
43.5, 40.9, 26.8, 22.2, 20.1; MS (ES
+
) m/z 374.1 (M+H)
+
. 
Benzoxazinorifamycin (2b). A mixture of aminophenol 7 (0.336 g, 1.5 mmol), rifamycin S (12; 
2.085 g, 3 mmol) and 1,4-dioxane (20 mL) was stirred at room temperature overnight. The 
mixture was then concentrated to a black solid and dissolved into 20 mL of methanol followed 
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by the addition of MnO2 (0.3 g, 3.45 mmol). The mixture was stirred at room temperature for 30 
min and MnO2 was filtered over Celite®. Methanol was removed to give dark residue which was 
purified by flash silica gel chromatography eluting with dichloromethane : methanol (95 : 5 to 
90 : 10). Product fractions were combined and concentrated to give partially purified 2b as a 
deep purple solid. Further purification by preparative TLC was conducted on a 20 mg scale, 
eluting the plate with dichloromethane : methanol (90 : 10). The yield is ~55%. Rf = 0.58 
(dichloromethane : methanol, 85 : 15); HPLC tR 6.1 min (95.4% purity); 
1
H NMR (CDCl3)  
7.48 (t, J = 8.4 Hz, 1 H), 6.92 (d, J = 8.2 Hz, 2 H), 5.98 (d, J = 15.4 Hz, 2 H), 5.14 (bs, 2 H), 4.97 
(m, 1 H), 4.41 (t, J = 11.6, 2 H), 3.29 (s, 2 H), 3.13 (s, 1 H), 3.08 (s, 3 H), 3.01 (d, J = 9.3, 2 H), 
2.65 (m, 4 H), 2.29 (s, 3 H), 2.09 (s, 3 H), 2.05 (s, 3 H), 1.79 (s, 3 H), 1.70 (m, 2 H), 1.60 (m, 2 
H), 1.25 (s, 3 H), 1.15 (t, J = 7.1 Hz, 6 H), 0.94 (d, J = 7.1 Hz, 3 H), 0.76 (d, J = 6.9 Hz, 3 H), 
0.63 (d, J = 7.1 Hz, 3 H); MS (ES
+
) m/z 900.1 (M+H)
+
; HRMS (MALDI) calcd for C49H61N3O13 
[(M + H)
+
], 900.4277; found 900.4269. 
Benzoxazinorifamycin (2c) A mixture of aminophenol 11a (80 mg, 0.22 mmol), rifamycin S 
(12; 220 mg, 0.32 mmol) and 1,2-dichloroethane (10 mL) was stirred at room temperature for 16 
h. . The reaction mixture was then concentrated to a black solid and dissolved into 10 mL of 
methanol followed by the addition of MnO2 (80 mg, 0.92 mmol). The mixture was stirred at 
room temperature for 30 min and MnO2 was filtered over Celite®. Methanol was removed to 
give dark residue which was loaded directly onto a flash silica gel column, and was eluted with 
dichloromethane/methanol/ NH4OH (94 : 6 : 0.5). Product fractions were pooled and 
concentrated to give a solid that was further purification by preparative TLC, eluting the plate 
with dichloromethane/methanol (92 : 8). The product band was processed to give 2c (170 mg, 
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74%) as a dark purple solid: HPLC tR 5.15 min (91.7% purity); 
1
H NMR (CDCl3)  7.56 (s, 1 H), 
7.48 (t, J = 8.4 Hz, 1 H), 7.04 (s, 1 H), 6.98 (s, 1 H), 6.92 (d, J = 8.3 Hz, 1 H), 6.80 (d, J = 8.2 Hz, 
1 H), 5.97 (m, 2 H), 5.12 (bs, 2 H), 4.94 (m, 1 H), 4.24 (t, J = 5.6 Hz, 2 H), 4.03 (t, J = 6.5 Hz, 2 
H), 3.09 (s, 3 H), 3.01 (d, J = 9.3 Hz, 1 H), 2.68 (m, 2 H), 2.52 (bs, 11 H), 2.29, (s, 3 H), 2.09 (s, 
3 H), 2.05 (s, 6 H), 1.80 (s, 5 H), 1.69 (m, 2 H), 1.60 (m, 2 H), 1.25 (s, 3 H), 0.93 (s, 3 H), 0.75 (s, 
3 H), 0.64 (s, 3 H); MS (ES
+
) m/z 1035.1 (M+H)
+
; HRMS (MALDI) calcd for C49H61N3O13 [(M 
+ H)
+
], 1035.5074; found 1035.5095. 
Benzoxazinorifamycin (2d) Reaction of a mixture of aminophenol 11b (30 mg, 0.08 mmol), 
rifamycin S (12; 102 mg, 0.15 mmol) and 1,2-dichloroethane (4 mL) and subsequent purification 
were carried out exactly as described above for the synthesis of 2c to provide 2d (29 mg, 34.5%) 
as a dark purple solid: HPLC tR = 5.11 min (91.8% purity); 
1
H NMR (CDCl3)  7.50 (m, 2 H), 
7.10 (s, 1 H), 6.95 (m, 2 H), 6.87 (d, J = 8.3 Hz, 1 H), 5.98 (s, 1 H), 5.96 (s, 1 H), 5.30 (s, 2 H), 
4.95 (m, 1 H), 4.76 (m, 2 H), 4.25 (m, 2 H), 3.68 (s, 1 H), 3.63 (s, 1 H), 3.49 (s, 1 H), 3.44 (s, 1 
H), 3.11 (s, 3 H), 3.03 (s, 1 H), 2.58 (m, 2 H), 2.51 (m, 4 H), 2.29 (s, 3 H), 2.09 (s, 3 H), 2.06 (s, 
3 H), 1.86 (d, J = 8.5 Hz, 1 H), 1.80 (s, 3 H), 1.68 (s, 2 H), 1.61 (bs, 9 H), 1.25 (s, 3 H), 0.94 (s, 3 
H), 0.75 (s, 3 H), 0.65 (s, 3 H). MS (ES
+
) m/z 1049.2 (M+H)
+
; HRMS (MALDI) calcd for 
C49H61N3O13 [(M + H)
+
], 1049.4866; found 1049.4857. 
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A1.4 Figures 
 
Figure A1.1. Structures of reference agents (1a, 1b, 2a) and novel benzoxazinorifamycins 
(2b−d). 
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Scheme A1.1. Synthesis of 2b-2d. Reagents and conditions: (a) benzyl bromide (for 3) and 1,4-
dibromobutane (for 5), Cs2CO3, DMF, 25 °C, 12−16 h, 93−95%; (b) BCl3, DCM, −78 °C, 1 h, 
82%; (c) Et2NCH2CH2Cl·HCl, Cs2CO3, acetone, 50 °C, 3 h, 93%; (d) 20% Pd/C, H2 (40 psi), 
25 °C, 20−40 h, MeOH/HOAc (9:1) for 6; MeOH/10% aqueous HCl (9:1) for 9a, 10; 81 − 98%; 
(e) 1-[2-(1H-imidazol-1-yl)ethyl]piperazine or 1-Boc-piperazine, DIPEA, CH3CN, reflux, 12−18 
h, 68−99%; (f) TFA, DCM, 25 °C, 3 h; (g) 2-(1H-imidazol-1-yl)acetic acid, DIPEA, EDC·HCl, 
HOBT, DMF, 25 °C, 16 h, 72% from 9b; (h) 7, 11a, or 11b; p-dioxane or 1,2-DCE, MnO2, 
25 °C to reflux, 35−74%. 
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APPENDICES 2  
STUDY ON THE FACTORS RESPONSIBLE FOR THE LOW BIOAVAILABILITY OF 
DABIGATRAN ETEXILATE 
A2.1 Introduction: 
Dabigatran etexilate (DE; Pradaxa
®
, Boehringer Ingelheim Pharma GmbH & Co.) is approved as 
an oral anticoagulant for the prevention of stroke and thromboembolism in the form of a prodrug 
of the active ingredient, dabigatran.
1-4
  DE is a weak base with its pKa values of 4.0 and 6.7. Its 
solubility is low at neutral pH (3 µg/mL at pH 7.4) and it increases with decreasing pH.
5
  An 
intrinsic permeability of 2.9 x 10
-5
 cm/s was determined in Caco-2 cell monolayer (log P = 3.8) 
which is comparable to that of metoprolol.
6-7
  DE with high permeability and low solubility is 
classified as BCS IIb compound based on Biopharmaceutical Classification System (BCS).
8
  DE 
has only 6-7% bioavailability when administrated as capsules.
9
  The low solubility can be one of 
the potential reasons, other factors also have to be investigated for the poor oral bioavailability. 
The disintegration and dissolution are the first steps for the oral absorption of drug products as 
well as the rate determining step for BCS II compounds (low solubility and high permeability). 
This process is significantly influenced by the formulation content, dosage form, and 
biopharmaceutical properties of specific drug substance.  Therefore the in vitro dissolution of DE 
was interrogated here as the first factor to understand the absorption mechanism. The most 
commonly used USP dissolution apparatuses for dissolution tests are unable to accurately reflect 
100 
 
the dissolution of DE in the gastrointestinal (GI) tract with dynamic fluid volumes and pH 
changes. In this report we utilized a recently developed three compartments GastroIntestinal 
Simulator (GIS) apparatus to evaluate the in vitro dissolution profiles of DE capsules under 
dynamic pH conditions.
10
  GIS system with separate gastric, duodenal and jejunal chambers 
could test in vitro dissolution of medications in fed/fasted condition by different gastric half-
emptying time. The in vitro dissolution of metoprolol (BCS I) was tested with GIS system, and 
the observed dissolution profile was similar to the clinical studies under the gastric half-
emptying time of 5-10 min.
10
  In this report we adopted a gastric half-emptying time of 8 min to 
check the supersaturation and precipitation conditions of DE with capsule formulation under 
dynamic changes of pH in each chamber. Clinical study on DE 150 mg capsule showed that its 
bioavailability reduced to 70% in the patients concomitantly treated with pantoprazole (a proton 
pump inhibitor) relative to the ones without pantoprazole, indicating the impact of pH changes 
on the DE absorption.
11-12
  Thus two sets of gastric buffers with pH of 2 and 6 were chosen to 
simulate the clinical studies with and without pantoprazole. 
The prodrug dabigatran etexilate, but not dabigatran, is a substrate of P-glycoprotein (P-gp).
5-6
  
P-gp is one of the efflux transporters presenting along human intestinal tract and is another factor 
that could potentially affect the bioavailability of DE. As a P-gp substrate, DE is reported to have 
an efflux ratio of 13.8 in the Caco-2 monolayer transport study and the ratio was brought to 1 
after P-gp activity was completely inhibited
6
. Clinically the bioavailability of DE capsule could 
be increased from 6.5 % to 15.6 % by pre-treatment with verapamil
13
 and to 10.1% with 
clarithromycin.
14
  When the patients were treated with rifampicin, a strong inducer of P-gp,
15
  the 
DE absorptions were reduced more than half compared to those without rifampicin.
16
  
Transporter-mediated drug-drug interaction (DDI) studies were also conducted among DE and 
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many other known P-gp substrates and demonstrated significant interference of P-gp-mediated 
transport.
17
   
Nevertheless, when examining the expression of P-gp transport within the small intestine, the 
upper segments of the GI tract where major absorption occur have low amounts of P-gp 
expressed while its amount increases along the GI tract.
18
  Furthermore, some BCSII/IV drugs as 
P-gp substrates could have good oral bioavailability as summarized in table 1. All of the reported 
results suggest that P-gp is an important factor, but other factors, like solubility and stability, 
need to be taken into consideration to fully understand the absorption mechanism. 
DE has two pro-moieties: an ethyl ester and a hexyl carbamate, and the hydrolysis of either of 
them will lower its permeability. Human carboxylesterase 1 and 2 (CES1 and CES2) have been 
reported accounting for the enzymatic hydrolysis of both pro-moieties,
15
  and such hydrolysis 
was also inhibited by non-specific CES inhibitor in Caco-2 cell line.
6
  In this report, the 
enzymatic degradation of DE was evaluated with human pancreatic tissue, human intestinal 
tissue and mouse intestinal fluid, to best mimic human digestive juices and the stability is 
compared with several ester prodrugs. 
Solubility, in vitro dissolution rate, transporter mediated drug efflux, and chemical/enzymatic 
stability of DE are discussed here to address the potential factors affecting the bioavailability of 
dabigatran etexilate capsules. The results combined with previously reported clinical data 
suggest that the P-gp efflux effect and the enzymatic degradation of DE in GI tract are important 
factors for the low absorptions. Solubility of DE is increased significantly by the capsule 
components, thus plays a minor role in the absorption process.  
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A2.2 Results 
Evaluation of solubility in DE absorption 
The solubility of pure DE was tested at different pH values as illustrated in the solubility - pH 
curve (Figure 1). The lowest solubility is 2-3 µg/mL in buffer with pH > 5 while it increases by 
more than 1000-fold when the pH decreases. When only the solubility factor is considered in the 
DE absorption, the dissolution and absorption were postulated with a GastroPlus
TM
 simulation by 
applying the measured solubility - pH curve as a parameter. P-gp and enzymatic effects were not 
applied in the virtual trials in this case. Results were plotted as a function of time for the first 24 
h (Figure 2a, Table 2). DE was rapidly dissolved and precipitated in the first hour which was 
consistent with in vivo pH changes, and then more dissolved gradually with the absorption 
increased (Figure 2a dotted line). The total bioavailability (solid line) eventually reached about 
80%. Discrepancy in the bioavailability from GastroPlus
TM
 compared with clinical data (6-7 %) 
9
 
could be observed when only evaluating solubility factor. This in silico postulation indicated the 
existence of other factors affecting DE absorption that are yet to be uncovered. 
Dissolution profiles of DE capsules 
In vitro dissolution profiles of dabigatran etexilate under dynamic pH changes were studied with 
GIS system. Gastric fluid and secretion buffers at two pH-value sets, 2.0 and 6.0, were adopted 
here to simulate clinical studies of orally administrated DE capsule with and without 
pantoprazole. Duodenal fluid buffer (50 mM PBS, pH 6.5) and duodenal secretion buffer (100 
mM PBS, pH 6.5) were kept unchanged in both sets. Mixed buffers from gastric and duodenal 
chambers were transferred to a jejunal chamber after the experiment began. Crude samples were 
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collected every 3 minutes in a 2 - 47 min time frame from every chamber and centrifuged at 
16,100 x g for 1.5 min. Supernatants were collected, mixed with 1 equivalent volume of 
methanol and analyzed as dissolution concentrations. Crude samples were then vortexed well, 
kept still at room temperature for 24 h, processed as above and analyzed as equilibrium 
concentrations.  
As illustrated in figure 3, DE dissolved well in the gastric chamber at either pH 6.0 or 2.0, 
although the concentration didn’t increase until 10 min after the experiment began caused by the 
disintegration rate (Figure 3a, 3d). After reaching a peak concentration at around 25 min, the 
concentration began to fall, indicating that all dosed drug was dissolved at this time point in the 
gastric chamber. The pumps for gastric transfer and secretion were set to stop at 48 min based on 
the gastric emptying time and the final amount of buffer remaining in gastric chamber. No 
significant concentration differences were observed in the samples after 24 hr, suggesting no 
supersaturation effect in the gastric chamber. This dissolution pattern was then confirmed by pH 
variations in gastric chamber, which were monitored by pH meters after each sample was drawn. 
The acidity of the gastric buffer at pH 6.0 was decreased by the components in the capsule, 
resulting in the increase of corresponding DE solubility (Figure 3g, dotted line).  
In the duodenal chamber, the two sets of dissolutions were similar in the early stage but different 
later. Supersaturation was observed much sooner in experimental set of pH 6 than in the set of 
pH 2 (Figure 3e); however the dissolution concentration was not dramatically affected by the 
supersaturation effect. Similar to the gastric chamber, the buffer pH in duodenal chamber was 
also influenced by the acidic components in the DE capsule as illustrated in figure 3h.  
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Both the dissolution and equilibrium concentrations in the jejunal chamber with gastric pH of 6 
were lower compared to those of gastric pH of 2, which suggests the impact from gastric pH on 
the dissolution of DE in the jejunal chamber (Figure 3c, f and h). Precipitations were observed in 
both sets, but were more pronounced in pH 6 experimental set. Generally, although both 
precipitation and supersaturation were observed in the jejunum chamber, the dissolved 
concentrations of DE could be increased by as much as 100-fold relative to pure DE, caused by 
the strong buffering ability of acidic components from the DE capsule. 
Degradation of dabigatran etexilate 
The chemical stability of DE was tested in buffers of pH 2.0 and 6.5, and found to be stable over 
24 h (data not shown) as reported previously.
6
  Besides chemical degradation, various hydrolases 
such as esterases, and peptidases exist in GI tract secretions, which could potentially hydrolyze 
DE. To best mimic degradation of DE in human pancreatic juice, DE was tested in human 
pancreatic tissue (HP) homogenate and mouse instestinal fluid (MIF). The degradation rate of 
DE was very fast in HP homogenate, showing a half-life of 24 ± 5 min, with the hydrolysis rate 
of the carbamate group 2-3 fold higher than the ester group (Figure 4)., The hydrolysis of both 
ester and carbamate groups was not inhibited by bis(4-nitrophenyl) phosphate (BNPP, known 
human carboxylesterases inhibitor
6, 9, 19
) in HP homogenate, but could be greatly inhibited by 
fluorophosphonate-PEG-rh (FP; a comprehensive serine hydrolase inhibitor
20
). The hydrolysis 
rates of DE and other ethyl ester prodrugs in MIF and human intestinal (HI) homogenate are 
listed in table 3 for comparison. In both HP homogenate and MIF, DE is hydrolyzed significantly 
faster than other prodrugs while rate differences are not significant in HI homogenate.  
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A2.3 Discussion  
Solubility and dissolution issues are not significant contributors to the low bioavailability of 
DE capsules 
Small-molecular therapeutic agents falling in the BCS II classification are characterized by high 
permeability and low solubility. Thus the solubility is always considered as their limitation 
during oral absorption process. The dissolution profiles for such drug products are required as 
important criteria to demonstrate bioequivalence. The solubility of dabigatran etexilate (DE), a 
weak base varies by more than 1000-fold under different pH conditions. To reflect the variation 
that dynamic pH condition poses on DE solubility, in vitro dissolution of DE capsules was tested 
in the gastrointestinal simulator (GIS) system.   
In blank experiments without any tested drug products (Figure 3g-i), the pH value of duodenal 
buffer in GIS was lowered in the beginning by gastric buffer (pH 2.0). Duodenal buffer pH 
returned to neutral range when the buffer transfer rate decreased and more duodenal secretion 
buffer (100 mM PBS, pH 6.5) was added. On the other hand when DE capsule was added, 
duodenal buffer stayed acidic until most of the components in the capsule were transferred to the 
jejunal chamber after 40 min. When the gastric buffer was set to pH 6.0, it was acidified by the 
DE capsule. Such an acidic environment further extended to the duodenal and jejunal chambers.  
The buffer system selected in our GIS study may not present in vivo due to the in vivo 
complexities and individual variations (fed or fasted). The goal in GIS in vitro dissolution studies 
outlined here is to demonstrate the impact of supersaturation effects and acidic components from 
the capsule formulation on the in vitro DE dissolution. The solubility of DE is improved 
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significantly by such effects in in vitro tests. The in vivo dissolution of DE capsule in the upper 
GI tract should provide equivalent or higher drug concentration in the case that the in vivo buffer 
system in fasted state is not stronger than that were used in our in vitro study.
21-22
  In the human 
fed state, high-fat, high-calorie food does not affect the bioavailability of DE but only postpones 
its absorption,
12
  and the in vitro test in such situation was not discussed in this report. Thus 
greatly increased concentrations of DE could be created by the supersaturation effect and acidic 
environment among dynamic pH environments, suggesting that solubility is not a significant 
contributor to the low bioavailability of DE in upper GI tract. 
DE is rapidly degraded by digestive enzymes 
Dabigatran, when dosed through i.v. infusion, was predominantly excreted via the urine 
(85.4%).
9
  The prodrug dabigatran etexilate (DE) was predominantly excreted in feces (>80%) as 
dabigatran following p.o. administration of the DE capsule in a clinical radiolabeled 
pharmacokinetics study.
9
  This can only be explained by hypothesizing that DE is degraded to 
dabigatran in the GI tract before absorption, considering dabigatran is not a P-gp substrate.
6, 17
 
Degradation within the GI tract is a common phenomenon for drugs and prodrugs. The 
compounds with ester, amide, or even ether bond are vulnerable to chemical or enzymatic 
hydrolysis before absorption. When DE is transferred to duodenum and mixed with digestive 
juices, degradation starts. Based on the clinical studies, high concentrations of DE should be 
maintained in the duodenum and jejunum. DE was then rapidly hydrolyzed in lower parts of the 
GI tract with reduced concentration and eventually excreted as unabsorbed dabigatran. This 
assumption is also supported by a recent clinical study on the coadministration of clopidogrel 
and DE.
23
  Clopidogrel is a prodrug that affects the hydrolysis of ethyl ester prodrugs through 
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drug-drug interactions
24
.  When it is concomitantly administrated with DE, the bioavailability 
increased to 135% (AUC) relative to the studies without clopedogrel.  
Interestingly, the hydrolysis of DE in HP homogenate could not be inhibited by BNPP, 
indicating that DE is hydrolyzed by other hydrolases besides CES1 and CES2. The hydrolysis 
results pointed out that other unknown activating enzyme with high efficacy against DE have yet 
to be uncovered in pancreatic tissue. 
Collectively, the absorption mechanism of the DE capsule is depicted in figure 5. After DE is 
released from capsules and dissolved in the stomach, it enters the duodenum where it mixes with 
digesting juices. DE maintains a high concentration due to supersaturation effects, with less 
involvement of P-gp efflux and enzymatic degradation through duodenum to upper jejunum. 
While moving through the GI tract, DE precipitates out with the increasing pH and is effluxed by 
the P-gp transporter. Eventually, DE is hydrolyzed to dabigatran and then excreted. Its low oral 
bioavailability generally results from a combination of solubility, P-gp efflux and enzymatic 
degradation. Among these factors, DE solubility has the minor impact to the poor absorption of 
DE capsule.  
A2.4 Experimental materials 
Chemicals 
Dabigatran etexilate mesylate 150 mg capsules (Pradaxa; Boehringer Ingelheim Pharma GmbH 
& Co), dabigatran etexilate free base (Shanghai Race Chemical Co., Ltd. Shanghai, China), 
Oseltamivir phosphate (Allichem LLC Baltimore, MD), Benazepril HCl (Selleck Chemicals, 
Houseton, TX) were purchased from commercial sources. Hydrochloric acid, sodium chloride, 
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sodium phosphate monobasic, acetonitril, trifluoroacetic acid, enalapril maleate, methanol and 
BNPP were purchased from Sigma-Aldrich Chemicals Co. (St. Louis, MO). FP-PEG-rhodamine 
were prepared as previously described
25
. Human small intestinal and human pancreatic tissues 
were obtained from the Tissue Core of the University of Michigan Comprehensive Cancer 
Center (UMCCC).  
Dabigatran Etexilate Solubility Study 
Phosphate buffers were prepared by sodium monobasic phosphate of 50 mM in DI water and pH 
values were adjusted to 2.0, 2.5, 3.0, 3.8, 4.0, 5.0, and 5.5 by hydrochloric acid or sodium 
hydroxide respectively. Extra amount of DE free base was added to the phosphate buffers and 
incubated at 37 °C with occasional vertex for 30 min. After centrifuged at 16,100 x g for 10 min 
at room temperature, supernatant was pipetted out and mix well with equal amount of methanol. 
Samples were then analyzed together with DE standard solution in methanol by an Agilent 1100 
HPLC system. Briefly, chromatography was performed on a 4.6 x 150 mm 3.5 micron ZORBAX 
Eclipse XDB-C18 column (Agilent), and samples were eluted with an 9 min gradient of 20%- 90% 
buffer B (Buffer A: H2O with 0.1% TFA; Buffer B: ACN with 0.1% TFA).  
Dissolution Study  
Dissolution studies by gastrointestinal simulator were performed as previously described
10
. 
Briefly, gastric, duodenal and jejunal chambers, are maintained at 37°C with stirring. Four 
pumps simulating gastric secretion, duodenal secretion, gastric emptying and duodenal emptying 
were calibrated before experiments started. Gastric-emptying time of 8 min was adopted in the 
experiments to simulate human fasted state. The gastric chamber was filled with 50 mL of 0.01 
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N HCl (pH 2.0) as gastric fluid and 250 mL of DI water as dose volume. Duodenal chamber was 
filled with 50 mL of 50 mM phosphate buffer (pH 6.5) and jejunal chamber was left empty. 
When the experiment started, the simulated gastric secretions (0.01 N HCl, pH 2.0) and duodenal 
secretion (100 mM phosphate buffer, pH 6.5) were pumped into gastric chamber and duodenal 
chamber at 1 mL/min, respectively. Gastric fluid were transferred into duodenal chamber 
following first-order rate (t1/2 = 8 min). The fluid in duodenal chamber was transferred into 
jejunal chamber by duodenal - jejunal transferring pump which kept the duodenal fluid volume 
constant at 50 mL during the dissolution study. When simulating impact of pantoprazole, 
stomach fluid buffer and secretion buffer were replaced by 1 x 10
-6
 N HCl (pH 6.0) buffer, and 
other buffers and parameters were kept the same. 
Crude solutions were sampled every 3 min from 2 min to 47 min from each chamber. After 
centrifuged at 16.100 x g for 1.5 min, supernatants were taken carefully, mixed with equal 
volume of methanol and analyzed as dissolution concentration by HPLC. Crude solution samples 
at each time point were vortexed, kept at room temperature for 24 h, then centrifuged and treated 
the same as above as equilibrium concentration. pH changes were monitored by pH meter every 
3 min after crude samples were taken.  
GastroPlus
TM
 Simulation 
The physicochemical and biopharmaceutical parameters of DE used in GastroPlus prediction are 
listed in Table 1. The solubility - pH curve from DE solubility study was used for the simulation. 
The variations in population physiology were defined as means with coefficients of variation and 
individual trials (n = 250) were randomly selected within those ranges. An initial dose of 150 mg 
with a dosing volume of 250 mL was selected in immediate release form (capsule). The gastric 
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emptying time of 15 min was adopted as a mean value. Other parameters were set based on 
previous report.
8
  
Human tissue homogenates 
The obtained human tissues were rinsed with phosphate buffer (50mM, pH7.4) for three times 
then grinded with a mortar and a pestle in liquid nitrogen. The yielded frozen powder was 
transferred to Dounce homogenizer, mixed with sterilized PBS buffer (50 mM, pH 7.4) and 
homogenized at 0 °C. Debris was pelleted by centrifugation for 5 min at 1,000 x g. Protein 
concentration was determined by the BCA assay and aliquots of the proteome were stored at -
80 °C until use. 
Collection of mouse intestinal fluid 
All animal experiments were conducted using protocols approved by the University of Michigan 
Committee of Use and Care of Animals (UCUCA). The animals were housed and handled 
according to the University of Michigan Unit for Laboratory Animal Medicine guidelines. 
Mouse intestinal fluid (MIF) was collected from male BALB/c mice (Charles River, IN) 
weighing 20−25 g. Mice were sacrificed by CO2 and intestines (~ 20 cm) were cut off from 
upper duodenum. PBS buffer of 400 µL (50 mM, pH 7.4) was flush into the intestinal tract. The 
liquid was squeezed out by hands gently, mixed and centrifuged at 16,100 x g for 5 min to 
remove feces. Protein concentration was determined by BCA assay and aliquots of the proteome 
were stored at -80 °C until use. 
Enzymatic hydrolysis of dabigatran etexilate 
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Proteome samples (1 mg/mL) were treated with vehicle, BNPP (100 µM) or FP (5 µM) for 30 
min at 37 °C in 50 mM Tris buffer (pH 7.4). DE was then added and incubated for 0, 15, 30, and 
60 min or 2 h, 3 h (depended on different enzymatic activities).  Reactions were terminated by 
equal volume of acetonitrile with 0.1% TFA and centrifuged at 16,100 x g for 5 min. 
Supernatants were filtered by with Microplate PVDF filter and analysed by an Agilent 1100 
HPLC system. Briefly, chromatography was performed on a 4.6 x 150 mm 3.5 micron ZORBAX 
Eclipse XDB-C18 column (Agilent), and samples were eluted with an 11 min gradient of 2%- 
90% buffer B (Buffer A: H2O with 0.1% TFA; Buffer B: ACN with 0.1% TFA). The hydrolysis 
rates of products generated were calculated based on the relative areas under the curve of the 
prodrugs and products. 
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A2.5 Figures 
 
Figure A2.1. Solubility vs pH value curve of DE. DE was added to phosphate buffers with 
different acidity (as noted in figure) until saturated and incubated at 37 °C for 30 min with 
occasional vertex. Samples were centrifuged at 16,100 x g for 5min and supernatant was mixed 
well with equal volume of methanol as unknown samples. DE standard solution was prepared by 
dissolving DE in methanol. Unknown samples and standard solutions were analyzed together by 
HPCL. Results are represented as the average ± S.D. of 2-3 individual experiments. 
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Figure A2.2. Amount of dissolved and absorbed dabigatran etexilate predicted by 
GastroPlus
TM
: (a) percentage of DE relative to total dose in 24 h. (b) percentage of DE absorbed 
in each GI segment. 
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Figure A2.3. In vivo predictive dissolutions by gastrointestinal simulator. When pH value of 
stomach fluid and secretion buffers are at 2.0, the dissolution results of gastric chamber (a), 
duodenal chamber (b) and jejunal chamber (c); when pH value of stomach fluid and secretion 
buffers are at 6.0, the dissolution results of gastric chamber (d), duodenal chamber (e) and jejunal 
chamber (f); pH changes were monitored at each time point in gastric chamber (g), duodenal 
chamber (h) and jejunal chamber (i). Error bars represent S.D. of 3-4 independent experiments in 
dissolution study. pH values were presented as mean values of 2-3 independent experiments.  
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Figure A2.4. DE hydrolysis in human pancreatic tissue. Human pancreas homogenate (1 
mg/mL) in Tris buffer (50 mM, pH 7.4) was treated with vehicle, BNPP and FP for 30 min, 
following the addition of DE at 37 °C. Samples were collected at 0, 15, 30 and 60 min, and then 
analyzed by HPCL. Results are represented as the average ± SEM of 2-3 individual experiments. 
 
 
 
Figure A2.5. Absorption mechanism of dabigatran etexilate. 
Pancrease
Duodenum
Jejumun
Ileum
Stomach
Stage 1: DE is released
and dissolved in stomach
Stage 2: DE is mixed
with digestive juice 
and starts being 
absorbed in duodenum
Stage 3: DE begins to precipitate
out due to increased pH; P-gp get 
involved more in the efflux of DE.
Stage 4: DE absorption is 
affected by enzymatic 
degradation, P-gp efflux and
solubility issue together
Stage 5: DE is eventually hydrolyzed to dabigatran, 
leading its non-absorption in colon. 
Colon
Liver
117 
 
Table A2.1. List of BCSIIb drugs. 
Compound BCS class LogP pKa Pgp substrate bioavailability 
dipyridamole II 3.71 6.47 yes 27-59%
26
 
itraconazole II 6.2 3.7 yes 55%
27
 
cefpodoxime IV 0.05 3.2 yes 50%
28
 
atazanavir II 6.46 4.7 yes 60-68%
29
 
indinavir II / IV 5.62 3.8 / 6.2 yes 63%
30
 
dasatinib II 1.8 3.1 / 6.8 yes well absorbed >50%
31
 
erlotinib II 2.87 5.4 yes 59%
32
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Table A2.2. Chemical/physiological/pharmacological parameters of dabigatran etexilate for 
GastoPlus
TM
 simulation 
Molecular weight 627.32 
5
 pKa 4.0 
5
 
Dose 150 mg 
4
 
Mean precipitation 
time 900 s 
Dose number 300 
A
 Human Peff 4.02 x 10
-4
 cm
2
/s 
6,B
 
Dose volume 250 mL Body weight 80.2 kg 
9
 
Solubility (pH 7.4) 0.003 mg/mL 
5
 Vc 1.25 L/kg 
9
 
log P 3.8 
5
 CL 0.1162 L/h/kg 
9
 
Vc: Volume of Central Compartment. 
A
 Calculated by GastroPlus
TM
. 
B
 Converted from Caco-2 perfusion coefficient by GastroPlus
TM
. 
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Table A2.3. Hydrolysis rate (nmol/min/mg) of dabigatran etexilate in different protein 
homogenates. 
 
HP MIF HI 
DE 17.2 ± 1.18 2.5 ± 0.5 0.63 ± 0.19 
Benezapril 
0.87 ± 0.2 
0.83 ± 
0.08 
0.108 ± 0.02 
Oseltamivir <0.1 <0.1 <0.1 
Enalapril <0.1 <0.1 <0.1 
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